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ABSTRACT OF DISSERTATION

IMMUNOTHERAPY IN COMBINATION WITH BEHAVIORAL
ENRICHMENT IN A CANINE MODEL OF AGING
Alzheimer’s disease (AD) is characterized by cognitive decline and hallmark
neuropathology, including β-amyloid (Aβ). Therapeutic strategies for AD are
focusing on reducing Aβ. Canines develop Aβ neuropathology and cognitive
decline with age similar to AD patients. In previous studies, immunization with
Aβ1-42 (VAC) in aged canines decreased brain Aβ but did not improve cognition.
Behavioral enrichment (ENR) improved cognition without reducing brain Aβ. We
hypothesized that VAC combined with ENR would provide cognitive benefits and
reduce Aβ neuropathology, as compared individual VAC and ENR treatments.
Aged beagles were placed into groups: control, VAC with fibrillar Aβ1-42, ENR,
and combination treatment (VAC+ENR) for 18 months. Learning and memory was
evaluated throughout the study. Serum IgG antibody titers, cerebral spinal fluid
(CSF) and brain Aβ were measured. Serum anti-Aβ1-42 IgG increased
significantly in VAC animals. ENR but not VAC significantly increased CSF Aβ140. No cognitive improvements were observed in any group. VAC significantly
reduced brain Aβ1-40 and 1-42, as well as reduced plaque load. An overall
slowing of plaque accumulation was seen in the ENR group. VAC and ENR were
able to modify pathology when used as separate treatments; however, the
combination treatment did not succeed in further reducing Aβ or improving
cognition. Previous AD clinical trials using immunotherapy yielded similar
outcomes to our study showing reduced Aβ pathology but little to no cognitive
improvements. In combination these results suggest that future studies should
focus on prevention approaches both in the canine model and in human clinical
trials.
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CHAPTER ONE: Alzheimer’s disease
Frequency of Alzheimer’s disease in the US and Internationally
In the United States, 5.4 million people are living with Alzheimer disease
(AD), (178, 495, 496). The number of people living with the disease is expected
to triple by 2050. This increase in prevalence of AD is thought to be due to the
general population living longer as well as the “baby boom” generation reaching
the age of 75, a time at which the most common late onset of the disease is seen
(22, 323). AD occurrence increases exponentially between the ages of 75 and 85
with about 50% of the population over the age of 85 being affected (113, 121, 178).
In 2010, the Center for Disease Control and Prevention reported 83,494 deaths
due to AD. However, a recent study by James et al. indicated the death toll may
be closer to 500,000 placing AD as the 3rd top killer in the US as opposed to its
previous place at 6th. Only heart disease and cancer are higher than AD in number
of deaths per year (197).
Economic Impact
Not only is the prevalence and number of deaths caused by AD increasing,
but the global economy is significantly impacted. The estimated annual global
economic burden due to dementia is between $315 and $604 billion (189, 486).
These vast costs come as little surprise with 12% of the population being elderly,
of whom make up 26% of physician visits, one third of hospital stays and
prescriptions, 40% of emergency responses, and 90% of nursing home residents
(22). These numbers will only grow as noted earlier due to the aging “baby boom”
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population. By 2029, all “baby boomers” will be at least 65 years old totaling an
estimated 70 million people in the US aged 65 years and older.
In 2009, the Alzheimer’s Association totaled direct costs to Medicare and
Medicare as well as indirect costs to businesses for employees who are caregivers
of individuals with AD and other dementias to be estimated at more than $203
billion in 2013 and expected to increase to $1.2 trillion in 2050 (23, 150, 224). In
2008, the average individual out of pocket costs for Medicare beneficiaries over
the age of 65 with AD and other dementias was $9,754 per person per year for
healthcare and long-term care services, with the payments being highest for those
living in nursing homes and assisted living facilities (22, 23). The total costs in
2004 from all sources of hospice care for these beneficiaries totaled $2.8 billion
(22). In addition to these expenses, are those that were not paid to individuals
who voluntarily cared for those with dementia. Whether it was family, a friend, or
neighbor, over 15 million people provided unpaid care for an individual with AD or
other dementia in 2008 (9, 22, 23). In 2012, these caregivers totaled 17.5 billion
(22, 448). The time provided by these caregivers is valued at $216 billion dollars
(22, 448). For perspective, the value of caregiver time totaled in 2011 equaled half
the net sales from Walmart and eight times the sales of McDonald’s (448). While
AD is quickly becoming an epidemic among the elderly, so has the cost of care for
these individuals on the US economy.
History
AD was first described in1906, by Dr. Alois Alzheimer after treating a patient
who exhibited progressive memory decline (10). Augusta Deter, a 51 year-old
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woman, died 5 years later after she was first seen by Dr. Alzheimer (10, 431). It
was noted at autopsy that the patient’s cerebral cortex was atrophied (10). At this
time, Alzheimer also identified histopathological changes that would later come to
be known as the hallmark lesions of AD, neuritic plaques and neurofibrillary tangles
(NFTs). In 1910, Emil Kraepelin named presenile dementia “Alzheimer’s disease”
to honor Alois Alzheimer (395, 431). A clinical diagnosis of AD is made when a
patient exhibits dementia with progressive decline, although a final diagnosis of
AD cannot be confirmed until post mortem examination and requires the presence
of AD pathological findings (96).
Cognitive and Behavioral Changes
A diagnosis of dementia is established when an individual exhibits the loss
of 2 or more of the following cognitive domains: memory, language, calculation,
orientation, or judgment (1, 2). However, for the individual to have a “probable AD”
diagnosis, they must have dementia that is clinically documented along with
deficits in at least 2 cognitive domains, absence of other systemic disorders, and
progressive worsening of memory (269, 270, 336, 338). Individuals with AD show
difficulty remembering new information and exhibit confusion, disorganized
thinking, impaired judgment, and disorientation with time, space and location.

In

addition, those with AD experience frequent changes in mood, are easily agitated,
and often experience anxiety.

These psychological changes often lead to

restlessness and sleep deprivation (12, 208, 285). Most AD patients require
assistance with bathing, dressing, using the bathroom, eating, and other daily
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activities. The gradual decline in memory eventually increases in severity until the
symptoms become debilitating (35).
If not noted by patient report or by a family member, friend, or caregiver, the
first signs of cognitive impairment can be detected through direct observation by a
clinician during an Annual Wellness Visit (15). If symptoms of cognitive impairment
are present, a brief structured patient assessment of cognition is performed using
one of several available tools including the Mini-Mental State Examination
(MMSE), the Memory Impairment Screen (MIS), the General Practitioner
Assessment of Cognition (GPCOG), or the Mini-Cog (59, 183, 192, 249, 281). In
addition, informant assessments of the patient can be conducted using the
GPCOG, AD8, or short Informant Questionnaire on Cognitive Decline in the Elderly
(IQCODE). If any of these assessments indicate possible cognitive impairment, a
full dementia evaluation can be conducted and may include an assessment of
multiple cognitive domains, a neurologic exam, standard laboratory tests, and
structural brain imaging. Results of a full dementia evaluation will help determine
an appropriate diagnosis such as mild cognitive impairment or AD, or determine
other possible causes (75).
Familial and Sporadic Alzheimer’s disease
There are two types of AD, familial and sporadic. When at least two
generations of a family has been reported to have AD with a mutation that is
inherited, it is considered of the familial type (41, 303). Sporadic AD occurs with
some genetic or outside contributing factors increasing one’s risk.

AD is further

defined as being early (EOAD) or late onset (LOAD) based on the age of onset of
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the disease. EOAD occurs before the age of 65 and LOAD occurs after (37, 497).
Almost all cases of sporadic AD are LOAD. EOAD makes 1-6% of AD cases of
which 60% are familial AD (57, 63). While familial AD must have a genetic
component, sporadic forms of AD may also have a genetic component (76, 77,
333, 350-355). However, a majority of the cases are unpredictable with various
factors including past medical history, environment, and lifestyle factors that may
increase or decrease the risk of AD and the age of onset.
Genetic Contributions to AD
Of the 60% familial cases that are EOAD, 13% are due to autosomal
dominant inheritance of specific genes (57, 63). Researchers have found several
genes to be associated with AD, but the three most commonly linked to familial
EOAD include mutations on the amyloid precursor protein (APP), presenilin 1
(PSEN1), and presenilin 2 (PSEN2) genes (141, 243, 244, 348, 349, 397). Over
200 mutations are reported in these three genes alone (35). A consistent feature
of all these mutations is elevated Aβ peptide levels (discussed in more detail later),
enhanced aggregation of Aβ, early onset of AD neuropathology, and cognitive
decline (25). The APP gene encodes an integral type 1 membrane glycoprotein
and when cleaved by beta and gamma secretases results in different Aβ peptide
isoforms. Mutations in APP result in altered ratios of Aβ isoforms in the brain and
can account for 10-15% of familial autosomal dominant EOAD cases (157, 339).
The PSEN1 and PSEN2 genes encode two proteins that are components of the
gamma-secretase complex, which are expressed in many different tissues
including the brain and are involved in cleaving APP to Aβ (242-244, 348). APP
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processing will be discussed in further detail in Chapter 2. The mutations reported
in PSEN1 and PSEN2 may result in a modified gamma secretase cleavage of APP.
This altered cleavage activity leads to altered Aβ ratios with an increase in AB 1-42
(107). PSEN1 accounts for a majority of the reported mutations and is the most
common cause of familial EOAD making up 18-50% of the autosomal dominant
cases (382, 432, 447).
Only one gene has been widely studied as the strongest risk factor for
sporadic LOAD, apolipoprotein E (APOE). APOE is a three-allele polymorphism
(ε2, ε3, ε4) encoding for a glycoprotein that carries cholesterol in the blood stream
and maintains lipid metabolism and transport (22, 76, 77, 349, 402). Additionally
it can influence the clearance of cerebral Aβ in AD individuals (76, 77). The effect
APOE has on AD depends on which alleles are expressed. ApoE2 has exhibited
protective properties and can act on longevity, ApoE4 increases the risk of AD,
and ApoE3 is considered neutral (76, 77). Humans express two alleles of APOE.
The effects of the two alleles a person expresses act in a dose dependent manner
(76, 77). For example, having at least one ApoE4 allele leads to a higher risk of
developing LOAD compared to individuals with no ApoE4 allele. However, the risk
of AD is 15 fold higher in homozygous carriers of ApoE4 (21). Individuals with
ApoE4 show more Aβ and NFT pathology when compared to individuals with other
ApoE allele expression (35). The risk of developing AD by ApoE genotype can be
modified further by non-genetic factors such as head trauma or stroke (184, 185,
300). The frequencies and distribution of the ApoE alleles vary widely among
populations (504, 505) however the ApoE3 allele is the most commonly expressed
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(35). APOE, along with APP, PSEN1, and PSEN2 make up less than 30% of the
genetic variance in EOAD and LOAD, however, many other genes are currently
being studied and reported (89, 431).
Non-Genetic Contributions
While APOE can influence risk of LOAD, other non-genetic variables can
increase, or decrease risk as well. Risk of AD increases with age, female gender,
and lower education (121, 236, 430). Females have a risk of AD three times higher
than that of males (125). This may be due to the fact that women on average live
longer than men, allowing more time for the development of AD (22). Education
is an important factor influencing risk of AD (210-212, 421, 422, 506).

The

supporting idea for this risk is that individuals with higher education develop a
greater “cognitive reserve capacity” than those with lower education (422). By
having a greater reserve, a maintenance of cognition or delay of dementia onset
may occur as a consequence of compensating for any functional deficits caused
by AD pathology (11).
Comorbidities can also influence AD risk.

Individuals with systemic

hypertension, diabetes mellitus, cardiovascular disease, and cerebrovascular
disease all experience a greater risk for developing AD (191, 229, 251, 265, 306,
412). Those with type II diabetes have a two-fold increased risk for AD (117, 250,
251, 317). Middle-aged individuals with high serum cholesterol levels are also at
a higher risk of AD later in age (220, 481). Observational studies have shown midlife hypertension to increases likelihood of AD (267). However, low blood pressure
later in life can also increase chances of developing AD (334, 356). History of
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traumatic brain injury or stroke dramatically increases risk of AD (122, 318),
especially in APOE4 carriers. Some environmental factors that also appear to
contribute to risk of AD include lack of social engagement, smoking, and heavy
alcohol drinking. Individuals who are ApoE4 carriers are especially affected by
smoking and heavy drinking (4, 16, 273, 311).
Protective Factors
While there are several factors that increase the risk of developing AD, there
are also several that are associated with reduced risk of disease including social
and cognitive enrichment, physical activity, and diet (112, 372, 373, 466). Exercise
activates

neural

plasticity,

vascularization (38, 80, 462).

remodels

neuronal

circuitry,

and

promotes

Cognitive enrichment such as reading, social

activities, knitting, tabletop games, information processing activities, and playing
musical instruments have all shown to be protective and reduce risk of dementia
and AD (36, 84). Diet has been widely studied for protective factors against the
development of sporadic AD. Omega-3, vitamin D, and folic acid have all been
shown to reduce risk of AD (110, 289-292, 374, 472). In addition, several studies
suggest that a Mediterranean diet of vegetables, legumes, fruits, and cereals,
unsaturated fats, fish, some dairy, meat and poultry, and wine is also associated
with decreased risk (415). While genetic factors and medical history can influence
the onset of AD, there are many lifestyle practices an individual can engage in to
reduce their risk.
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Neuropathology of AD
In parallel, or prior to, the development of cognitive and behavioral changes,
individuals with AD accumulate several types of neuropathology that become
progressively worse as the disease evolves. In the 1960’s, the 2 classic lesions of
AD, NFTs and senile plaques, were confirmed as hallmark pathology for the
disease (215, 431). During the 1980s, various neurotransmitter deficits were
identified in AD (146, 147, 298, 329). Additional forms of neuropathology that
contribute to AD have also been described including changes in brain volume,
synaptic and neuronal loss, as well as decreased neurogenesis. A brief description
of each of these key pathologies is described next.
Brain Volume and Neuronal Loss
The medial temporal lobe, including the hippocampus and entorhinal cortex,
is the first area in the brain to show atrophy in individuals with AD and occurs early
in the disease as shown with structural MRI (26, 48, 52, 106, 216, 337, 414, 449,
450). Atrophy, including loss of myelination, synapses, and neurons, begins in
the temporal lobe and develops into the neocortex, notably the frontal and parietal
regions, at later stages of the disease (26, 48, 52, 73, 90, 106, 188, 195, 284, 380,
414, 449).

Several longitudinal studies have shown that increased rates of

ventricular widening as well as regional and whole brain atrophy in otherwise
healthy individuals increases risk of developing cognitive decline due to AD later
in life (64, 196, 357). Several studies have indicated a strong correlation between
cognitive ability and synaptic numbers (93, 247, 369, 375, 377-379, 441). With the
loss of synaptic contacts and neurons, a significant reduction of grey matter in the
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hippocampus and entorhinal cortex is seen in later stages of AD (308). This grey
matter loss correlates with decreased cognitive performance, especially so with
memory (227, 439).

However, synaptic and neuronal loss is experienced in

multiple regions of the brain in AD, possibly explaining the diverse cognitive
changes seen with the progression of the disease (376).
Neurogenesis
Neurogenesis takes place primarily in two regions of the adult brain, the
subgranular zone of the dentate gyrus of the hippocampus and subventricular zone
of the lateral ventricles (111). Fully functioning neurons can be generated from
progenitor cells. These cells proliferate into immature neurons and migrate to the
granule cell layer where they mature and integrate into preexisting circuitry (502).
Interestingly, several genetic contributors to familial AD modulate neurogenesis,
including PS1 and APP (237). While PS1 positively regulates neural progenitor
cell differentiation, soluble APP positively regulates proliferation (62, 126, 127,
238). However, mutations in these two genes, as seen in familial AD, alter alpha
and gamma secretase activity and reduce soluble APP, respectively, which may
suppress neurogenesis (as reviewed in (237)).

These deficiencies in

neurogenesis may occur early in AD, prior to plaques, NFT, or neuronal loss, thus
further supporting the idea that familial AD involved proteins directly affect
neurogenesis which may contribute to the development of AD (238).
The link between changes in learning and memory with age and losses in
neurogenesis is complex (237). The hippocampus is one of the first regions of the
brain affected in AD, and is also one of only two brain regions where neurogenesis
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occurs. Thus supporting the hypothesis that pathological processes of AD impact
neurogenesis, and vice versa (161, 205, 206, 248, 386, 467, 468, 508). It has
been proposed that when these disease processes begin to take place, rates of
neurogenesis will increase in attempt to compensate before a significant loss in
neurogenesis is observed (5, 222, 228, 248, 399, 400). Decreases in neurogenesis
may underlie cognitive impairments associated with dementia (69, 161, 205, 206,
237, 248, 386, 467, 468, 508). Suppressing neurogenesis causes deficits in
hippocampal dependent learning; while other cognitive domains appear unaffected
(238, 507). Furthermore, additional studies that increase neurogenesis in mice
lead to improved performance in pattern separation and spatial memory (363,
423).
Neurofibrillary Tangles
In 1963, neurofibrillary tangles (NFTs) were first identified as one of the
hallmark lesions of AD and found to be made up of paired helical filaments (PHFs)
(190, 215, 431). Then in 1986, researchers found that NFTs were comprised of
microtubule associated protein tau (58, 151, 225, 304, 494). Tau protein has a
normal function of stabilizing microtubule formation and disassembly in neurons.
In its non-phosphorylated state, tau protein binds microtubules and binds less
tightly once phosphorylated (56). However, increased phosphorylation, or hyperphosphorylation, of tau can lead to aggregation of the protein within the cell and
formation of paired helical filaments (PHF) (151). Ultimately these PHFs lead to
the formation of neurofibrillary tangles (NFT) (142, 226, 240, 264). There are 19
specific amino acid sequences that are frequently phosphorylated in the formation
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of NFTs in AD (29, 142, 226, 240, 264). Tau protein can be phosphorylated by
several kinases, but the three commonly acting on phosphorylation sites of interest
in AD include MAP kinase, GSK-3 and cdk5 (104, 254).
The extent and distribution of NFTs correlates with the severity of dementia
in AD (20, 49). There are different morphological stages of NFTs including pre-,
intra-, and extra- neuronal (219). Pre-neuronal NFTs include intracellular punctate
aggregates of hyperphosphorylated tau inside an otherwise healthy neuron. Once
these aggregates start to form filamentous structures, paired helical filaments
(PHFs), an NFT is then considered intra-neuronal.

NFTs enter the final

morphological stage, extra-neuronal, when the neuron dies and only an extra
cellular NFT, or “ghost tangle”, remains (219).
In addition to morphological changes, NFTs have defined stages for
progression in terms of severity and location within the brain known as Braak
stages I-VI (19, 52). A 900 autopsy case study spanning the ages 25 to 95 of
demented and non-demented brains showed that younger cases showed a pattern
of NFT deposition that spread with more advanced ages (307). NFTs are first
observed in layer II of the entorhinal cortex (transentorhinal cortex) following a
predictable sequence spreading onward to other regions of the brain (19, 20, 50,
53, 187, 326, 460, 461). Braak stages I and II are defined as having NFTs present
in the transentorhinal region of the brain with the absence of cognitive impairments
(55, 200). At these stages, this area is generally void of any Aβ deposits of plaques
(54). Progression into Braak stages III and IV show more extensive NFT pathology
into the hippocampus, however, most of the neocortex is unaffected. When NFTs
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reach the hippocampus, limbic circuits become disrupted that is associated with
declines in cognition seen at these stages. This disruption is further exacerbated
in Braak stages V and VI when NFTs are prevalent throughout the cerebral cortex.
These stages of neuropathology are used for confirmation of clinical AD diagnosis
(283, 451). NFTs have been seen in other neurodegenerative diseases in the
absence of Aβ pathology, and it can be assumed that NFTs can occur
independently of plaques in the progression of AD (389). This is seen in Braak
stages I and II of NFT progression. However, for a final diagnosis of AD, the
presence of senile plaques is also required.
β-Amyloid
In addition to NFTs, a final diagnosis of AD at post mortem examination also
requires the presence of Aβ plaques (33, 96, 201).

As with most of the

neuropathology observed in AD, Aβ pathology occurs early in the disease before
cognitive impairments are observed (389). Genetic mutations of APP, PSEN1, or
PSEN2 seen in familial AD can influence the age at which Aβ pathology is first
seen. According to the amyloid cascade hypothesis, excess accumulation of Aβ
peptide induces a series of events including the formation of insoluble and soluble
oligomers followed by aggregate stress, the formation of NFTs, and ultimately
leading to neuronal death and AD (159). At the start of the cascade, APP is
cleaved by β- and γ- secretase and the resultant cleavage product is the Aβ
peptide (476). Depending on the location at which γ- secretase cleaves APP,
various species of Aβ peptide can be produced. The two most common Aβ peptide
species are Aβ1-40 and Aβ1-42 (194, 389). These Aβ peptides can accumulate into
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oligomers, then fibrils, which then aggregate further to make up Aβ plaques (97,
138, 261).

The spatial pattern of Aβ deposition begins in the frontal cortex

spreading to the lateral and parietal regions early in the disease (18, 50-52, 445).
Later, Aβ deposition spreads further into the occipital lobe and motor cortices with
the entorhinal cortex and hippocampal region being affected last (18, 51). Whether
Aβ deposition directly causes neuronal loss is unknown, but Aβ is toxic and can
alter neuron function (294). For example, many studies have shown Aβ deposition
impairs long term potentiation, a physiological substrate for memory, and neuronal
plasticity in the hippocampus (245, 389).
The extent of Aβ pathology including peptide production and isoforms, the
various types of plaques that form, and effects on cognition will be described in
greater detail in the following chapter.
Vascular Aβ and Cerebral Amyloid Angiopathy
In addition to Aβ plaques, Aβ peptides can deposit in association with the
vasculature (138).

Aβ was originally isolated from meningeal blood vessels of

individuals with Down syndrome and AD (138, 139). Aβ deposition in vascular
walls is characteristic of cerebral amyloid angiopathy (CAA) (138, 389). CAA is
defined as amyloid protein aggregated within the blood vessels of brain tissue that
can be stained by Congo red, an immunohistochemical stain that labels compacted
amyloid protein aggregates (342). While Aβ protein makes up Aβ plaques and
CAA, there is a low correlation between the two events and each can occur in
absence of the other (389, 465). Population studies show that 55-59% of patients
with dementia show CAA and in up to 98% of the AD cases (199, 214). Though
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the majority of the AD population shows CAA in the brain, the degree of CAA
burden among individuals with AD can vary widely (389, 465). Genetic mutations
associated with AD, including APOE and PSEN1, are also risk factors for CAA
deposition (149, 299, 325, 499). While CAA can be found throughout the brain,
the distribution pattern is much like that of Aβ plaques beginning in the frontal,
parietal, temporal, and occipital cortices and later in the hippocampus and
entorhinal cortex (443, 444). Interestingly, a study documenting and assessing
various forms of neurodegenerative pathology in relation to cognitive function
indicated that CAA may correlate more strongly with the presence of dementia
than with other forms of amyloid pathology (266). However, the contribution of CAA
to dementia is not well understood (465).
Accumulation of Aβ in the vasculature may be due to efforts of clearing the
peptide from the brain or microglial uptake and deposition into the vascular lumen.
Vascular Aβ deposition prompts smooth muscle cells of these vessels to produce
vascular Aβ, allowing further Aβ deposition. Affected vessels show thickened walls
with amyloid deposits and degeneration of smooth muscle cells (260, 301). On
rare occasion, advanced CAA damage of the vessel walls can cause them to
rupture resulting in microhemorrhages or hemorrhagic stroke (389, 489). When
hemorrhaging does occur, it is predominantly located in the frontoparietal,
temporal, and occipital regions of the brain. A definitive clinical diagnosis of CAArelated hemorrhages cannot be made until postmortem examination, but a
probable diagnosis can be made by MRI or CT imaging (223). In comparison, a
probable diagnosis of CAA can be made with the observation of multiple
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hemorrhages confined to lobar brain areas with no other explanation for the
pathology (148). Cerebral microhemorrhages are seen in 16.7 to 32% of AD
patients as seen using MRI (78, 79, 155, 156, 297). When using positron emission
tomography (PET) with amyloid labeling

11C-Pittsburgh

Compound B (PiB),

microhemorrhages usually occur in regions that have concentrated amyloid
deposits of individuals with and without AD (99).

Copyright © Paulina R. Davis 2014

16

CHAPTER TWO: β-Amyloid
APP and APP Processing
The Aβ peptide is a cleavage product of the amyloid precursor protein (APP)
(152, 153).

The Aβ peptide was first sequenced from amyloid deposits in

meningio-cerebral blood vessels of a patient with Down’s syndrome (DS) and AD
(137, 140). Subsequently, APP was localized to chromosome 21 (209, 343, 433).
APP is a single transmembrane polypeptide glycoprotein whose function is
unknown (476). APP is commonly cleaved between residues 16 and 17 of the Aβ
region by α-secretase resulting in a soluble ectodomain region (APPs-α) and its
release into vesicle lumens. Alternatively, APP can be cleaved by β-secretase
cutting APP to release a truncated form of soluble APP (APPs-β), which is also
released into the vesicle lumen (393). Cleavage by either α-secretase or βsecretase also results in a carboxy terminal fragment (CTF) still within the
membrane that will ultimately be cleaved by γ-secretase resulting in either the
peptide p3 (if first cleaved by α-secretases) or Aβ peptide (if first cleaved by βsecretase) (464, 500). The majority of APP undergoes processing by α- and γsecretases while less undergoes the amyloidogenic processing by β-secretase
and γ-secretase (387). Various mutations in APP or PSEN1 or PSEN2 genes, as
described in the genetic risk factors of AD section of Chapter 1, can lead to
increased amyloidogenic processing of APP. Genetic mutations identified in the
APP or PS gene causing AD in addition to the observation that older individuals
with trisomy 21 DS having an earlier onset of AD and faster progression of the
disease led to the amyloid hypothesis (141, 158, 179, 295, 309). The amyloid
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hypothesis proposes that production of Aβ and its intracellular deposition in
neurons along with extracellular formation of diffuse and neuritic plaques is the
initiating factor resulting in tau hyperphosphorylation and activation of microglia,
ultimately leading to neurodegeneration (119, 159).
Aβ Peptide
During the amyloidogenic processing of APP, γ-secretase can cleave the
CTF at various sites leading to multiple isoforms of Aβ peptide ranging from 36 to
43 amino acids long (74, 136, 194). The two most common isoforms of Aβ are Aβ140 and

Aβ1-42 which are 40 or 42 amino acids in length, respectively (74, 136, 194).

While the biological function of Aβ peptide is not well known, it does have a
hydrophobic structure that self-aggregates into dimers, trimers, tetramers,
oligomers, and fibrils (262). In general Aβ1-40 is more soluble, less toxic, and found
in plaques, but more commonly associated with deposition in the blood vessels
(324, 389, 498). Aβ1-42 on the other hand is more hydrophobic making it more
readily aggregated to form fibrils and plaques representing the majority of
parenchymal Aβ (324, 389, 477). Up to 90% of Aβ in the brains of individuals of
AD can be of the Aβ42 species (144). Individuals with familial AD due to APP
mutations will have increased levels of extracellular Aβ 1-42 or both Aβ1-40 and Aβ142

depending on the mutation (61, 68, 427), while PSEN1 or PSEN2 mutations

selectively increase Aβ1-42 levels (382).
Soluble and Insoluble Aβ
The various forms of Aβ can be either soluble or insoluble. The soluble
form of Aβ can be found in CSF, plasma, and serum as well as in brain tissue (262,
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390). Soluble CSF Aβ1-40 and Aβ1-42 can be used as biomarkers to predict AD
pathology progression in the brain (153, 394, 398). CSF Aβ1-42 is reduced in
individuals with AD and inversely proportional to the level of cognitive impairment
and Aβ pathology in the brain of that individual (13, 128). Generally, those without
AD have higher levels of CSF Aβ and lower levels of brain Aβ. Lower CSF Aβ
would indicate the movement of Aβ from the periphery into the brain (13, 128).
While CSF Aβ levels inversely correlate with AD pathology in the brain and
cognitive decline, Plasma Aβ1-40 and Aβ1-42 levels are more variable and less
reliable as a biomarker of AD (268, 272, 463). Additionally, the levels of Aβ1-40 and
Aβ1-42 are much higher and more easily measured in CSF than plasma Aβ 1-40 and
Aβ1-42 levels (268, 272, 463). The insoluble form of Aβ can only be found in tissue
(294, 473). Insoluble Aβ is generally fibrous in nature and makes up a large
proportion of Aβ plaques (262). The Aβ that forms plaque cores is generally more
insoluble than that from vascular deposits (262). While both soluble and insoluble
Aβ correlate with cognitive impairment, soluble Aβ levels measured by biochemical
assays appear to better correlate with cognition than insoluble dense plaque
deposition measured immunohistochemically (252, 271, 396).
Aβ Oligomers
Aβ is also very toxic in its soluble oligomeric form (252, 271). When Aβ
monomers assemble with one another they can form soluble oligomers which can
exist in multiple forms such as dimers, trimers, or Aβ*56 (a dodecameric Aβ
formation) (235). Two studies in the early 1990’s demonstrated a poor correlation
between fibrillar Aβ and cognitive decline in patients with AD (98, 442). Later
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soluble non-fibrillar Aβ levels were shown to have a strong correlation with AD
(252, 271). With these studies it was suggested that soluble Aβ may be a greater
contributor to progression of AD than the previously thought deposited fibrillar Aβ
(252, 271). Since Aβ oligomers provide more surface area for interaction with
neural synapses than plaques, they are thought to be more synaptotoxic.
Oligomers modulate both pre- and post-synaptic structure and functions in a dose
dependent manner (313, 388). This synaptotoxicity by oligomers causes inhibition
of long term potentiation in the hippocampus contributing to cognitive decline
(470).
Aβ Plaques
Aβ is deposited extracellularly and aggregates into plaques (389).

As

mentioned, Aβ is self-aggregating and first forms polymers that then create beta
pleated sheet formations making up Aβ fibrils (389). The insoluble Aβ fibrils may
be inactive but are reservoirs of smaller Aβ assemblies (153, 294, 394, 398).
These fibrils can then become cytotoxic when misfolded leading to amyloidosis
and aggregating to form Aβ plaques (389). Both Aβ1-40 and Aβ1-42 can be found in
plaques, but since Aβ1-42 is more fibrillogenic of the two it is observed in Aβ plaques
earlier in the disease (145, 193). Two types of plaques can form, diffuse and dense
plaques.

Diffuse plaques are primarily made of Aβ1-42, while dense plaques

contain both Aβ1-40 and Aβ1-42 (263). When stained by immunohistochemistry,
diffuse plaques have a cloud like structure while dense plaques are more globular.
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Post-translationally modified Aβ
Aside from the multiple Aβ isoforms that can result in the c-terminal
cleavage by γ-secretase, there can also be N-terminal heterogeneity (429). This
heterogeneity leads to various shorter peptides including Aβ5-40, Aβ5-42, Aβ3-40, and
Aβ3-42 (65, 429). Additional post-translational modifications can occur with these Ntruncated Aβ peptides. For example, an amino terminal modification can occur in
which there is a proteolytic removal of residues 1 and 2 (Asp and Ala) (287).
Another type of post-translational modification that can occur is the cyclizing of
residue 3 or 11 of Aβ (Glu) to a pyroglutamate (pE) by glutaminyl cyclase (QC)
(287, 384). The most prominent forms of the pEAβ species are Aβ 3(pE)-40, Aβ3(pE)42,

Aβ11(pE)-40, and Aβ11(pE)-42 (365). As stated earlier, up to 90% of Aβ in the brain

ends in Aβ42 (144). Truncated and modified Aβ make up most of the Aβ 42 in the
brain with Aβ3(pE)-42 being the most prevalent form (144, 428). The prevalence of
N-truncated and modified Aβ peptides is even greater in the brains of patients with
familial AD compared to those with sporadic AD suggesting that posttranslationally modified Aβ has a decisive role in the development of AD (282,
361). pEAβ is more readily aggregated, more toxic, and is resistant to degradation
(8, 162, 362, 383, 385, 487).

Schilling et al. studied the seeding and

oligomerization capacity of the pEAβ peptide species and found that formation of
seeds required for forming fibrils was very rapid compared to unmodified Aβ
peptide (383). This suggests the pEAβ peptide species is more toxic and could
initiate Aβ aggregation and plaque formation by unmodified Aβ (383). Since pEAβ
peptide species promotes the advancement of Aβ pathology early in AD, then this
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species could be a marker of older Aβ deposits (383).

With the N-terminal

pyroglutamyl present, pEAβ is resistant to N-terminal targeted degradation, adding
to the toxicity of this Aβ peptide species (364). These attributes suggest that the
pEAβ species plays a prominent role in the overall progression of AD (162, 186,
362, 383, 440) and may determine the severity of disease state in an individual
(360).
Not only is pEAβ involved with Aβ pathology in AD, but two recent studies
indicate an involvement in hyperphosphorylated tau pathology (256, 305). In 2012,
Nussbaum et al. examined the connections between pEAβ and tau in AD, finding
that the toxicity of pEAβ and tau were dependent on one another (305). Later,
Mandler et al in 2014 measured and compared pEAβ 3, full-length Aβ, and
hyperphosphorylated tau loads in the frontal cortex and entorhinal cortex of 41 post
mortem brains of both individuals with AD and controls (256). As expected, all
loads were higher in AD. Interestingly, when looking at pEAβ 3-x independently of
full-length Aβ, pEAβ3 predicted AD and hyperphosphorylated tau while full-length
Aβ only predicted AD (256). High levels of hyperphosphorylated tau came with
greater loads of pEAβ3, but were not affected by the absence of full-length Aβ
(256).

The greater toxicity, resistance to degradation, correlation with

hyperphosphorylated tau and the progression of AD make pEAβ a critical peptide
to evaluate in future AD studies and therapeutic development.

Copyright © Paulina R. Davis 2014
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CHAPTER THREE: Dog Model
Used previously published material with permission.
Davis, P.R., Head, E. Prevention approaches in a preclinical canine model of
Alzheimer’s disease: benefits and challenges. Front. Pharmacol. 2014: 5: 1-14
The Canine Model of Human Aging and Alzheimer’s disease
Some of the most commonly studied animal models of human brain aging
are rodents and nonhuman primates (129). Other animals, including wolves,
bears, cats, and dogs, naturally develop human-like neuropathology (172). Of
these animals, cats and dogs tend to have similar living environments to humans
(172). Canines, however, show cognitive decline with age and develop most
aspects of neuropathology seen in aged human brain including AD patients (81,
87). Such neuropathology includes Aβ pathology, reduced brain volume, neuronal
loss, and impaired neurogenesis (81, 163). In addition to the similar cognitive
decline and accumulation of neuropathological hallmarks to humans with AD,
drugs exhibit similar pharmacokinetics when administered to dogs or humans (for
example statins - (7, 132)), making them an appropriate model for translational
studies on therapeutic drugs. Not only are dogs easy to handle due to their long
history of domestication, but pet dogs also share similar living conditions and diets
to humans (30, 87, 316). Canines are highly motivated by food reward when
conducting cognitive tests, which makes them cooperative research subjects by
reducing or eliminating deprivation protocols for motivation.

Thus, this

cooperativeness eliminates many physiological stressors that can affect cognitive
testing results present in other animal models such as rodents that require food
deprivation or cold water for motivation (40). The similar cognitive decline and
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accumulation of neuropathology to humans makes the canine model of aging
useful for translational research on neurodegenerative diseases, especially AD.
Cognitive Outcome Measures
There are several measures of cognition that are age-sensitive and
treatment-sensitive in dogs that can be used as intervention outcome measures to
assess different cognitive abilities with analogous tasks in nonhuman primates and
in humans. Much like humans, the aging canine shows cognitive decline with
various cognitive domains and cortical pathways being differentially affected (277).
Dogs show cognitive deficits due to age in tests measuring complex learning,
executive function, spatial learning and attention, and memory (67, 82, 166, 277,
280, 410, 424, 434, 435, 437). In addition to cognitive domain variability, individual
dogs also show variability in cognitive function as seen in humans (3). This
variability becomes most apparent in old canines, and using spatial learning and
memory tasks, three groups of animals can be identified: (1) successful agers, (2)
impaired dogs whose scores fell 2 standard deviations above the mean of the
young animals, and (3) severely impaired dogs who failed to learn the task (172).
The availability of age-matched animals with and without cognitive deficits allowed
researchers to determine which types of neuropathology contribute to individual
cognitive impairments in these animals (e.g. (166)).
Several tasks, similar to those used for testing cognition in non-human
primates, have been developed to measure cognitive decline in the aging canine
(274, 276, 277). Such tasks include landmark discrimination, oddity discrimination,
object, size and black / white discrimination and reversal tasks, and a spatial
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memory task. Cognitive testing occur in a modified Wisconsin General Testing
Apparatus such that the motor and sensory demands are consistent across tasks
(277). For each task, 10-12 trials are given per day and dogs are tested daily until
a predetermined criterion level of performance is reached; total error scores are
added up across days to provide a measure of learning and/or memory for each
animal. These tasks are described in more detail below to illustrate how a test
battery can be developed to measure the function of several brain circuits that may
be differentially affected by age and/or treatment in aging dogs.
Landmark Discrimination Task
The landmark discrimination task, which measures visuospatial function
and allocentric learning, involves presenting dogs with two identical objects, one
of which is adjacent to a third object that serves as a landmark (274). Animals are
required to recognize that the landmark is an indicator of which object covers the
food reward, and selection of the object closest to this landmark by the animal is
considered a correct response. The task is made successively more difficult by
placing the landmark further away from the object covering the reward. Previous
work shows that aged dogs are impaired on the landmark task and show age
decrements in their ability to determine how close the landmark is to the correct
object (274, 276).
Oddity Discrimination Task
The oddity discrimination task measures complex learning, as well as
prefrontal cortex function (82). Aged dogs show deficits in oddity discrimination
learning (82, 280).

In this task, dogs are presented with three objects
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simultaneously, two of which are identical and a third that is unique. A correct
response is indicated when the dog chooses the unique object, resulting in a
reward. To prevent a floor effect and detect progressive age decline, the oddity
aspect of this task is made successively more difficult. Animals progress through
four sets of three objects and each subsequent set contains a unique object, which
is more difficult to distinguish from others than the previous set (280). Interestingly,
young dogs can solve this problem by using the strategy of selecting the novel
object for each successive set of objects such that error scores plateau; in contrast,
aged dogs do not learn a strategy but re-learn each set of objects as a new problem
(82, 280).
Object, Size and Black/White Discrimination
Tests of object, size and black/white discrimination are administered to
measure associative learning ability. Object discrimination involves presenting
dogs with two different objects simultaneously with one of the two objects
consistently rewarded. Dogs must learn to select the same object each
presentation with the left/right position being randomly determined. Similarly, the
size discrimination objects differ in size (small/large) and the black/white
discrimination task objects differ only in color (black/white) (278). Object, size and
black/white discrimination are also progressively more difficult for animals to solve
given the similarities in the objects increasing. Thus, these 3 tasks in combination
can serve as different test versions (much like in clinical studies in people) to
assess longitudinal changes in learning while reducing practice effects (278).
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Object, Size or Black/White Reversal
Executive function can be evaluated immediately after discrimination
learning has been completed by using the object, size or black/white reversal
tasks. The reversal tasks differ from the original discrimination task in that the
positive and negative objects for reward contingencies are reversed after animals
have learned the initial discrimination (278, 279).

Reversing the reward

contingencies can show perseverative behaviors (persistent choice of previously
correct object), which are frontal cortex dependent (474). A subset of the
discrimination learning tasks and all reversal learning tasks are age dependent,
with reversal learning being consistently more impaired with age (277-279, 410,
437).
Spatial Memory Task
Memory also declines with age in dogs. The most useful age-sensitive task
we have used is a spatial memory task, in which dogs are required to recognize
the location of a sample stimulus and then respond to a different location during
the test trial. We refer to this as a delayed non-match to position task (DNMP) and
it involves showing animals a single object covering a food reward either on the
left or right food well. After animals move the object and obtain the reward, the
object is withdrawn from sight for a predetermined delay period (e.g. 10s).
Subsequently animals are given two identical objects to choose from; one is the
same object in the same position as before and one is in a novel position. The
correct response is to select the object covering the novel location.

Results

published in 1995 (170) suggested that the task was age-sensitive. We
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subsequently developed a 3-choice visuospatial working memory task that allows
determination of the differential age-dependent strategies (e.g. cognitive or
stimulus-dependent strategies) dogs use in solving the problem (66). In this task,
rather than just the left and right food wells, a center well is also included to make
the task more difficult.

Further, this task shows minimal practice effects in

longitudinal studies (177). The time course of the development of cognitive decline
was identified and deterioration in spatial ability occurs early in the aging process,
between 6 and 7 years of age in dogs (424).
Behavioral/Functional Outcome Measures
In addition to cognitive outcome measures, researchers and veterinarians
are interested in measuring functional outcomes.

Further, laboratory-based

cognitive testing as described above is labor intensive and requires many months
to years to obtain data. An open field test can be used to observe the behavioral
patterns of animals in an empty room for 10 minutes. During this task, movement,
sniffing, urinating, grooming, rearing, jumping, vocalization, and inactivity are
noted (171, 409, 411). Self-recognition can be evaluated through the mirror test,
originally developed for primates (91, 130), by observing the reaction of each
animal with a mirror and their reflection. Exploratory behavior of canines can be
assessed through a curiosity test in which animals are presented with various
novel play objects. During their time with the objects, the amount of time the dogs
spend in physical contact with or sitting next to the objects is recorded as well as
their frequency of sniffing the objects (411). Social responsiveness of dogs can
be gauged through a few different tasks: a human interaction test, silhouette test,
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and the model dog test. A human interaction test is performed by the presence of
a person in the middle of the room and recording the reaction of the dog to that
person by measuring the time the dog is in physical contact with the person, time
sitting or standing beside the person, and frequency sniffing the person (167). The
silhouette test records the animals frequency of sniffing the front and rear regions
of a cardboard silhouette of a dog posted onto a wall (123). The model dog test
also records the sniffing frequency of the dogs, but this time in response to the
presence of a life size model dog in the center of a room (411).
Behavioral patterns in these functional tasks show age effects as well as
differential effects based on the presence of intact/impaired cognition. In 2001,
Siwak et al. characterized the behavioral profiles of young (2 to 4 years), aged (915 years) cognitively impaired, and aged non-impaired beagles (411). Young dogs
tend to show greater responsiveness to changes in environments such as the
addition of novel objects and a person.

They also showed greater social

responsiveness spending the most time next to or sniffing a person, silhouette,
and model dog. Aged unimpaired dogs were still responsive to alterations in
environment, but to a lesser degree than the young animals. Additionally, aged
unimpaired dogs spent the least amount of time reacting to the mirror during the
self-recognition task. Unlike either the young or aged unimpaired canines, the
aged impaired canines were unresponsive to all stimuli presented to the
environment and randomly moved about the room in pacing/aimless behavior.
However, the aged impaired dogs did spend the most time interacting with the
mirror in the self-recognition test (411).
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Measures of canine function can also be assessed in a clinical setting (231233). Clinical measures have been developed consisting of pet dog owner based
evaluation of dog behavioral changes (46, 47, 72, 233, 330, 331) similar to those
used in human clinical evaluations, such as the Mini Mental State Exam (MMSE).
Although there are different versions of these questionnaires, all appear to be
sensitive to the presence of canine cognitive dysfunction (233). The evaluation
consists of items such as walking, posture/emotion of expression, elimination
behavior, life rhythm, play behavior, exploratory behavior, learned specific
behavior, adaptive capabilities, and interactions with other animals or with owners.
The items of individual questionnaires can be used to derive scores that distinguish
between normally and pathologically aging dogs. Adult and older dogs generally
score worse with these types of evaluation tools, and old dogs show individual
variability in terms of the amount of cognitive dysfunction reported (47).
Dog Neuropathology and Outcome Measures
Just as canines can exhibit cognitive decline with age similar to aging
humans and patients with AD, several human-type neuropathologies have been
reported in dogs (81). In particular, the canine model has long been suggested as
an excellent model of Aβ pathogenesis (490). Several changes observed in the
aged canine brain are associated with cognition and are discussed below.
Brain Volume
Individuals with AD show significant cortical and hippocampal atrophy and
ventricular enlargement relative to non-demented age matched controls (6, 340)
and losses in brain volume correlate with cognitive decline (105, 114). Similar
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events are seen in aged canines. On cross sectional MR imaging, aging canines
show increased cortical atrophy and ventricular widening (143, 218, 425).
Ventricular widening over time was observed by MRI in a 3-year longitudinal study
(426). Canine cortical atrophy occurs earliest in the prefrontal cortex and later with
age in the hippocampus (436).

As with humans, the more extensive the

cortical/hippocampal atrophy seen in aged canines the more pronounced the
cognitive deficits (347, 436).
Neuronal Loss
There is some evidence for neuronal loss in AD that could account for brain
volume losses seen in brain imaging (404, 478). With normal brain aging, neuronal
loss is only seen in the hilus (478, 479), while neuronal loss is much more
widespread in individuals with AD (42, 480).

Individuals with AD experience

neuronal loss in the CA1, CA2, CA4, dentate gyrus and subiculum of the
hippocampus (42, 327, 480). In aged beagles, the hilus of the dentate gyrus
showed fewer neurons compared to younger dogs (408). Beagles with fewer
neurons in the hilus made significantly more errors when performing the size
discrimination task (408). Similarly, Pugliese et al. found that a loss of Purkinje
cells of the cerebellum in canines correlated with data acquired by questionnaires
quantifying behavioral deficits (330). However, neuronal loss may not account for
all of the brain atrophy observed by MR as the loss of neuronal dendritic spines
occurs with AD (221, 312) but to our knowledge, there are currently no studies
published evaluating similar changes with age in dogs.
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Neurogenesis
While selective neuronal loss may occur with aging, the brain is also able
to produce new neurons. The hippocampus, for example, grows new neurons in
the subgranular layer (111), as described in Chapter 1. Neurogenesis has been
explored in aged beagles using BrdU and doublecortin staining methods. SiwakTapp et al. measured neurogenesis in aged beagles using BrdU and found that
animals over the age of 13 showed a significant loss of neurogenesis (407). Fewer
newer BrdU positive neurons was associated with poorer cognitive function in
learning and memory (407).
Β-Amyloid
Beta-amyloid (Aβ) is derived from a longer precursor protein, the amyloid
precursor protein (APP). The APP sequence of Canis familiaris has 98% homology
with human APP (http://www.ensembl.org/Canis_familiaris/) and an identical
amino acid sequence (207, 391). Additionally, dog Aβ peptides may undergo the
same posttranslational modifications as in humans (31, 371). These similarities
make canines a viable aging model without the need for genetic modification or
overexpression of mutant human proteins (391).
The Aβ present in canines is ultrastructurally fibrillar and, though more
compact deposits may form, it generally aggregates into diffuse plaques (88, 133,
293, 359, 454, 455, 458). This type of Aβ deposition most resembles early AD
pathology (81, 257, 288) (Figure 3.1A). Since most AD therapeutics studied today
are likely to have a greater affect if applied earlier in the disease progression, the
early AD-like pathology canines produce makes them an attractive model for
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preclinical prevention studies (258).

As with cognitive decline, AD-like

neuropathology has a region specific progression in both humans and canines (52,
133, 168, 391, 445, 488). Though this progression in dogs is similar to that
reported in humans, it is not identical. In canines, the accumulation of Aβ begins
in the prefrontal cortex (approximately 8 years at age of onset) and continues to
develop with increasing age to include other regions such as the temporal and
occipital cortex (81, 168, 358). The severity of neuropathology can vary between
individual animals but can be linked to the extent of cognitive decline (72, 86, 169,
347). For instance, animals who perform worse in reversal learning tasks have
greater Aβ pathology in the prefrontal cortex, while those deficient in size
discrimination learning show higher amounts of Aβ in the entorhinal cortex (86,
166, 322).
Aβ peptide can also be measured in the cerebrospinal fluid (CSF) of dogs
(370). Measuring CSF Aβ as a ratio of Aβ42/ Aβ40 is a good predictor of Aβ in the
brain in dogs (176). While brain Aβ increases with age, CSF Aβ decreases with
age reflecting the hypothesis that Aβ migrates from the periphery and deposits in
the brain with age and AD.
Aside from the fibrillar Aβ found in diffuse plaques in AD, a smaller, more
soluble form of Aβ, oligomeric Aβ, - is also seen in the aged dog brain. This more
toxic form of Aβ affects synaptic function and can be found in plaques (213, 390,
471).

Higher levels of oligomers are present in canines and humans with

increasing age and cognitive decline. The greater the cognitive deficit, the more
prevalent oligomers are in the brain (321, 453). Similar to fibrillar Aβ, oligomeric
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Aβ can be measured in CSF, where levels are inversely related to levels in the
brain (176).
Cerebrovascular Pathology
Aβ can also aggregate in the cerebral blood vessel walls and cause
cerebrovascular pathology (27, 180, 328). This type of deposition is referred to as
cerebral amyloid angiopathy (CAA) (Figure 3.1B, C, D).

Typically CAA is

composed of the shorter Aβ 1-40 peptide (27, 180, 491). Both humans and
canines exhibit CAA pathology, with a particular vulnerability in the occipital cortex
(28).

CAA impairs the blood brain barrier, vascular function, and can cause

microhemorrhages and occasionally hemorrhagic strokes (92, 328, 456). Because
of these complications, CAA may contribute to cognitive decline in both humans
(27, 109, 302, 342) and canines (133, 164, 456, 457). Much like humans, canines
develop microhemorrhages with age (457) (Figure 3.1E).

These cerebral

hemorrhages are present in both animals with and without CAA, but are more
common in those with the blood vessel pathology (457). Given the significant
overlap of cerebrovascular pathology with AD, the spontaneous accumulation of
CAA in dogs also offers as yet, an underappreciated model system to test the
effects of cerebrovascular pathology on cognition and AD neuropathology.
Neurofibrillary Tangles
One hallmark AD pathology canines do not produce is NFTs (359, 391).
While no research to date has observed NFTs in the canine brain, the increased
phosphorylation seen at some sites of tau in AD cases also occurs in cognitively
impaired canines (173, 230, 315, 332, 475). This lack of NFT pathology could
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possibly be due to significant differences in the tau protein sequence between
canines and humans (http://www.ensembl.org/Canis_familiaris/). However, an
advantage to dogs not accumulating NFTs is that they serve as a model that is
selective for Aβ pathology and ideally suited for testing interventions that target
this toxic protein.
Treatment Studies in Aged Dogs
Several studies have investigated therapeutic strategies using the canine
model of aging and AD with both cognitive and neuropathological outcome
measures (Table 3.1).
Antioxidant-rich Diet in Combination with Behavioral Enrichment
One of the earliest studies to develop a treatment for cognitive dysfunction in
aged dogs tested an antioxidant-rich diet in combination with behavioral
enrichment in aged dogs.

The rationale for this study was observations of

increased oxidative damage in the canine brain (346, 347, 413) and studies in
mouse models of AD showing environmental enrichment benefited cognition and
reduced Aβ pathology (17, 202, 239). The diet included vitamins E and C, fruits
and vegetables, lipoic acid and carnitine. The behavioral enrichment included
increased exercise, interaction with other dogs, and cognitive enrichment (82, 276,
278, 279). Compared to control animals, those receiving an antioxidant-rich diet
committed fewer errors during landmark acquisition and retention tasks (276) as
well as oddity discrimination tasks (82). Treatment with an antioxidant diet and
behavioral enrichment resulted in improved performance during black and white
object discrimination and reversal (278). Pop and colleagues found dogs provided
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with both behavioral enrichment and an antioxidant diet have an overall reduction
in Aβ pathology across multiple regions of the brain (322) However, when looking
at group treatment effects, only the antioxidant-treated animals had a significant
reduction in Aβ plaque pathology.

Additionally, the combination treatment

approach of behavioral enrichment and an antioxidant-rich diet in aged canines
was unable to reduce existing brain Aβ, but was able to slow the accumulation of
Aβ (322). While plaque load was affected by the combined intervention, soluble
and insoluble Aβ1-40 was not reduced, and only soluble levels of Aβ1-42 were
lowered specifically in the prefrontal cortex. A trend towards a significant decrease
in oligomers, specifically in the parietal cortex, was observed in canines receiving
the combined treatment (322). Interestingly, the combination group also showed
reduced oxidative damage (310) with the antioxidant diet group alone showing
reduced mitochondrial dysfunction (175). Further, the behavioral enrichment
group, independent of the antioxidant diet treatment showed less neuron loss in
the hippocampus (408) as well as improved levels of brain derived neurotrophic
factor (115).
Supplemental Medium-Chain TAG
Supplemental medium-chain TAG (MCT) increases ketone levels in the
brain, and these ketones can in turn be used as an alternative energy source. In
2010, Pan and colleagues measured cognitive effects of this supplement on the
landmark discrimination, oddity discrimination, and 2 choice egocentric spatial
learning tasks.

Results indicated aged dogs given a diet with MCT
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supplementation performed better than those receiving a control diet in all tasks
(314).
Medical Food Cocktail
In contrast, fewer benefits on cognition were observed in a study using a
medical food cocktail (174). Dogs receiving a combination cocktail containing an
extract of turmeric containing 95% curcuminoids, an extract of green tea containing
50% epigallocatechingallate, N-acetyl cysteine, R-alpha lipoic acid and an extract
of black pepper containing 95% piperine exhibited fewer errors compared to
control animals during the landmark task indicating improved spatial attention.
However, other areas of cognition were unaffected and brain Aβ remained
unchanged (174).
Cholesterol-lowering Drugs
Several studies in the aged dog have tested the effects of drugs already
approved for use in humans, with novel applications to brain aging. For example,
several cross-sectional or case-control epidemiological studies revealed a striking
link between cholesterol-lowering drugs (e.g. statins and others) and a 20-70%
reduction in risk of developing AD (108, 154, 204, 344, 345, 492, 493, 503).
Modest cognitive benefits have been reported in preliminary AD clinical trials with
simvastatin (406) and atorvastatin (416-419). In particular, AD patients with mild
to moderate dementia who were treated with 80 mg/day atorvastatin had
significantly improved scores on one measure of cognition (ADAS-Cog) at 6
months of treatment, with smaller non-significant benefits at 12 months (419).
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Statins may reduce the risk of incident AD through the prevention of Aβ
production (160, 405). In rodent models, treatment with inhibitors of 3-hydroxy-3methylglutaryl coenzyme A (HMG-CoA) or statins reduces Aβ (319). However,
rodents respond to statin treatment by massively upregulating HMG-CoA
reductase levels (7, 118, 446, 452). To compensate, long-term studies in rodent
often employ physiologically excessive doses, making it difficult to translate the
results of these studies into human trials.
The dog model is particularly useful to study chronic statin treatment, given
similarities with humans in terms of dose requirements, responsiveness, drug
handling, and metabolism (7, 132). For example, 12 dogs were treated with 80
mg/day of atorvastatin for 14.5 months (296). Peripheral levels of cholesterol, low
density lipoproteins, triglycerides and high density lipoproteins were reduced in
treated dogs. Surprisingly, a transient impairment in reversal learning was
observed,

suggesting

prefrontal

dysfunction.

Spatial

memory

remained

unchanged up to over a year of treatment. The lack of cognitive benefits of
treatment was also reflected by a lack of reduction in plasma, CSF, and brain Aβ.
Interestingly, BACE1 protein level was decreased in the brains of atorvastatintreated dogs. This intriguing outcome may suggest that statins might be more
useful to prevent the production of Aβ through lowering BACE1 if started in animals
in middle age, consistent with human studies indicating that middle-aged
individuals using statins are protected from AD.
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Immunotherapy
In 2008, a therapeutic approach that directly targeted Aβ reduction was
explored in which aged beagles were actively immunized with fibrillar Aβ 1-42 for 2
years (VAC) based upon previous work in transgenic mouse models of AD (381).
Schenk and colleagues were one of the first groups to explore the immunotherapy
approach and found that active immunization with fibrillar Aβ1-42 reduced Aβ
pathology in aged mice while preventing accumulation in young mice (381).
Additionally, behavioral outcomes improved in treated mice (198, 286). When
testing this immunotherapy approach in a larger animal model, the aging caning,
results showed no improvement in cognitive function, but interestingly a long term
maintenance of executive function was noted based on error scores from the size
reversal learning task (177). However, significant benefits to brain pathology were
observed in the VAC dogs who showed significantly decreased Aβ plaque load in
prefrontal, entorhinal, and occipital cortical regions, as well as reduced CAA (177).
While soluble and insoluble brain Aβ1-40 and Aβ1-42 significantly decreased in
treated canines, there was no significant reduction in soluble oligomers. This study
suggests that reducing or eliminating pre-existing Aβ in aging dogs is not sufficient
to improve cognition.
Outcomes from the longitudinal dog active vaccination study are similar to
reports of Aβ immunotherapy clinical trials in patients with AD where no differences
between antibody responders and placebo groups on several cognitive and
disability scales was observed. A small number of patients enrolled in the AN1792
study have come to autopsy and show A plaque reduction without any effect on
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the extent of neurofibrillary tangles or CAA (120, 259, 301). Further, the frontal
cortex showed the largest response to immunotherapy (259), which is similar to
our observations in the dog. The most recent autopsy study of 8 patients that were
in the AN1792 study further confirm reduced Aβ pathology in response to
treatment, 5 years after the last injection (182). However, reduction of brain Aβ
did not slow disease progression and 7 of 8 patients had severe end stage
dementia prior to death. (134).

Interestingly, a composite score of a

neuropsychological test battery indicated “less worsening” of decline in antibody
responders after 12 months and an improvement in the memory domain (134).
In contrast, Bosch et al. recently (2013) showed benefits of an active fibrillar
Aβ40 and Aβx-40 combination vaccine on cognition in aged companion beagles and
pet dogs treated for 51 days

(46). Over the course of treatment, cognitive

evaluations by questionnaire were given at 31 days post treatment and at the end
of treatment. Immunized animals showed a significant improvement in cognitive
evaluation scores at both 31 and 51 days post treatment compared to preimmunized scores (46). Differences in the formulation, the outcome measures or
the source of animals may explain the positive effects in the Bosch study compared
with the previous beagle immunotherapy studies.

Copyright © Paulina R. Davis 2014
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Table 3.1. Treatment Studies in Aging Dogs
Treatment

Sample
size and
Age

Landmark
Discrim.

Oddity
Discrim.

Size
Discrim.

Size
Reversal

Black White
Discrim.

Black/white
Reversal

Spatial
Memory

Question
-naire

Publication

Improved

Improved

Improved

Improved

Improved

Improved

Improved

N/A

(82, 278, 279)

N/A

N/A

Improved

Improved

Improved

Improved

Improved

N/A

Improved

Improved

Improved

Improved

Improved

Improved

Improved

N/A

24 old
(9-10
yrs)
18 old
(8-9 yrs)

Not
Improv.

Impaired

N/A

N/A

N/A

N/A

Impaired

N/A

(314)

Improved

Not
Improv.

Not Improv.

Not Improv.

Not Improv.

Not Improv.

Not
Improv.

N/A

(174)

10 old
(9-13
yrs)
20 old
(8-13
yrs)
12 old
(11-18
yrs)

N/A

N/A

Not Improv.

Impaired

Not Improv.

Not Improv.

Not
Improv.

N/A

(296)

Not
Improv.

Not
Improv.

Not Improv.

Maintained

Not Improv.

Maintained

Not
Improv.

N/A

(177)

N/A

N/A

N/A

N/A

N/A

N/A

N/A

Improved

(46)

Antioxidant diet
Behavioral
Enrichment
Antioxidant Diet
+ Behavioral
Enrichment
MCT Dietary
supplement
Medical Food
Cocktail
Atorvastatin
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Fibrillar Aβ1-42
Immunotherapy
Fibrillar Aβ 1-40
& x-40
Immunotherapy

28 old
(8-13
yrs)
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Figure 3.1. Aβ Pathology in an Aged Beagle.
The prefrontal cortex of a 13.8 year old beagle immunostained with Aβ 1-16 (6E10)
showing Aβ deposition. Arrows indicate intact neurons within diffuse plaques (A).
CAA clustering in the prefrontal cortex of a 12.7 year old beagle immunostained
with Aβ 1-16 (6E10) (B). Cross section of a blood vessel with CAA in the prefrontal
cortex of a 14.5 year old beagle immunostained with Aβ 1-16 (6E10) (C). CAA
shown in a longitudinal blood vessel of a 13.7 year old beagle (occipital cortex)
stained with Congo red (C). Note the striations of CAA along the blood vessel wall
indicated by arrows (C). Microhemorrhages are seen by Prussian blue staining in
the prefrontal cortex of a 13.8 year old beagle (E). The arrow points to a cross
section of a blood vessel with a microhemorrhage and the arrowhead indicates a
hemosiderin laden perivascular microglia (E).
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CHAPTER FOUR: Significance and Rationale
Introduction
5.1 million people in the United States are affected by Alzheimer’s disease
(AD), the most common form of dementia, with no current treatment available
(495). As described in Chapter 1 (Alzheimer’s Disease), the hallmark lesions of
AD include neurofibrillary tangles (NFTs), and plaques made up of the β-amyloid
protein (Aβ) that result from cleavage of the amyloid precursor protein (APP) (255,
389). While there is no cure for AD, there are various approved drugs for use as
symptomatic treatments of AD. Three of these drugs are acetylcholinesterase
inhibitors, donepezil, rivastigmine, and galantamine, and a noncompetitive NMDAreceptor antagonist, memantine (124, 131). These drugs only act to manage the
symptoms of AD for a limited period of time until the symptoms are too great and
the drugs become ineffective. In addition, no current biomarker can determine
when AD pathology will occur or how it will progress in an individual, resulting in a
variable age of onset of disease. An individual may be clinically normal while their
brain may have sufficient pathology for an AD diagnosis (85). For those reasons,
researchers have spent the past several years developing numerous therapeutic
strategies to specifically reduce neuropathology and improve cognition in AD
patients (392)
An exciting therapeutic strategy being evaluated is immunotherapy
(immunization or vaccination).

Specifically, several immunotherapies being

explored target the reduction of Aβ.

This approach aims to reduce Aβ

accumulation and increase its clearance in AD patients with the goal of reversing
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cognitive decline due to the AD neuropathology. Both active and passive Aβ
immunotherapies have been explored by researchers.
Aβ Immunotherapy as a Therapeutic for AD
Active vaccination involves the administration of a vaccine containing an
antigen to induce the recipient’s immune response that produces antibodies
against that antigen. The benefit of this type of vaccine is that only a small number
of vaccinations are required to promote an immune response to produce
antibodies and maintain that response.

However, the disadvantage is the

variability in immune response between patients.

Passive immunotherapy

involves the delivery of antibodies against the antigen of interest derived from a
source other than the recipient. The benefit to this type of immunization is the
ability to administer the desired amount of therapeutic antibodies.

The

disadvantage is that passive immunization requires repeated injections or
infusions in order to maintain the desired antibody concentration in the recipient
over time (43, 44, 234).
The mechanism by which immunotherapy works is still unclear, however
there are several hypotheses. Only about 0.1% of antibodies in the periphery are
able to pass into the brain (43, 44, 203, 234). Although a majority of antibodies do
not pass into the brain, the volume of anti-amyloid antibodies in the periphery can
cause a “peripheral sink” effect driving the movement of Aβ out of the brain and
into the periphery (43, 44, 203, 234). This “peripheral sink” hypothesis has been
demonstrated in multiple animal models (94). Of the antibodies that do reach the
brain, several possible mechanisms could contribute to the reduction of Aβ levels
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and pathology. For one, the anti-Aβ antibodies could bind to soluble forms of Aβ
increasing their clearance or causing a shift of equilibria leading to insoluble Aβ
breaking down into a more soluble form (234). Antibodies could be binding to Aβ
plaques promoting microglial activation to aid in clearing out plaques (34, 43, 45,
301). Additionally, bound Aβ to antibodies may disrupt its ability to aggregate into
plaques (234).
Active vaccination with the Aβ peptide was first described by Schenk and
colleagues (381). A study of transgenic mice vaccinated with the Aβ peptide
demonstrated that not only was Aβ accumulation reduced in older animals with
pre-existing Aβ pathology, but it was prevented in younger mice (prior to Aβ
pathology) as well. In addition, behavioral outcomes were improved (198, 286).
As a result, the study progressed to a clinical trial in which mild to moderate AD
patients were immunized with fibrillar Aβ1-42 with QS-2 in polysorbate 80 as an
adjuvant (181). Promising initial data showed 20% of the AD patients developed
antibodies to fibrillar Aβ and had improved brain function (181). However, in a
second larger clinical trial in 2005, while some patients developed antibodies and
had reduced Aβ plaques, no cognitive improvement was seen, and the trial was
ultimately halted when a subset of patients developed aseptic meningoencephalitis
(135). Some of the patients who had developed meningoencephalitis possessed
an elevated t-cell response in the brain. This T-cell response is thought to be
associated with the adjuvant used in the vaccine, QS-2 in polysorbate 80 (135).
Subsequently,

a

second

generation

immunotherapy, has been developed.

of

immunotherapy,

passive

In 2010, there were 15 passive Aβ
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immunotherapies in clinical trials including bapineuzumab and solanezumab (241).
These two passive immunotherapies, like active immunotherapy, aim to remove
preexisting Aβ pathology and reduce cognitive decline.
Bapineuzumab is a humanized monoclonal antibody to Aβ 1-5. In mice, this
antibody reduced Aβ pathology (94, 438). In Phase III clinical trials, bapineuzumab
may have reduced Aβ accumulation and phosphorylated tau levels as seen in
cases that reached autopsy. However, the treatment failed to improve cognition in
patients with and without the ApoE4 allele, a gene that associated with an
increased risk of developing AD (341, 366, 367, 403). It was suggested that the
dosage of bapineuzumab used in the Phase III trials was too low to reach the
desired primary outcomes (366, 367), however Phase II trials using greater doses
resulted in more cases of edema and microhemorrhages in treated patients (368,
420). The doses used in Phase III trials showed no significant adverse effects due
to bapineuzumab treatment (366, 367).
Solanezumab, another humanized monoclonal antibody, targets Aβ16-24, and
reverses memory impairment in the PDAPP mouse model of AD (32, 94, 100, 438).
However, solanezumab immunotherapy leads to variable effects on Aβ burden
including both reduction (94) or no change (100). Solanezumab subsequently was
tested in two Phase III clinical trials, but both trials failed to meet prespecified
primary outcomes of improving cognition and function (101, 102). While primary
outcome measures were not met, a reduced rate of cognitive decline seen in
patients with mild AD was observed in one study (101, 102). Additionally, no
significant adverse effects are seen due to the solanezumab treatment (101, 102,
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401). Further studies will continue to explore solanezumab in patients with mild
AD or those who lack the clinical symptoms of AD but show brain Aβ accumulation
through biomarker measures (101, 102).
Although the passive immunotherapy approach was thought to be safer and
more promising than active vaccination since no adjuvant is needed,
bapineuzumab and solanezumab both failed to meet efficacy expectations and
fulfil primary outcomes of reducing or slowing down cognitive decline in AD
patients (101, 102, 341, 366, 367, 401, 403). Additionally, there are still concerns
with adverse effects such as edema and intracerebral microhemorrhages (60, 320,
368, 420, 483). Thus, there is a critical need to continue to refine and develop
novel therapeutics for AD.

Two possible reasons for negative clinical trials

outcomes are (1) the preclinical animal model was not a predictor of human clinical
trial outcomes and (2) the serious adverse events were harmful to the patients due
to the immunotherapies themselves.
Aβ Immunotherapy in the Canine Model of AD
In Chapter 3 we describe a unique animal model, the canine, which shows
similar neuropathology and cognitive decline to humans with AD.

Canines

naturally produce APP that has 98% homology with human APP, develop Aβ
neuropathology, and show cognitive decline with age, similar to AD patients (253,
277, 475, 501). The similar neuropathology and cognitive decline coupled with
their common living conditions with humans make dogs useful for translational
studies on neurodegenerative diseases such as AD.
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The active vaccine used in this study differs from past clinically tested active
vaccines in that it uses Aluminum hydroxide (Alum) as an adjuvant in place of the
QS-2 in polysorbate 80. This Alum adjuvant is commonly used in other active
vaccines that can be safely administered in humans and causes minimal, if any,
T-cell responses in the brain. As discussed in Chapter 3,in a study reported in
2008, aged beagles were actively immunized with fibrillar Aβ1-42 using Alum as
an adjuvant (VAC) for 2 years (177). In addition, VAC dogs had significantly
decreased Aβ plaque load (177). No serious adverse events such as those
reported in the previously described human clinical trials were reported. However,
Aβ immunotherapy in aging dogs with preexisting pathology led to no improvement
in cognitive function, but interestingly a long term maintenance of executive
function that was noted based on error scores from the size reversal learning task
(177). These results suggest that reducing Aβ alone was insufficient to improve
cognition but that over time, lower levels of brain Aβ can support cognitive
maintenance.
Behavioral Enrichment in the Canine Model of AD
Another therapeutic strategy being explored is behavioral enrichment.
Behavioral enrichment (ENR) includes environmental enrichment, exercise, social
engagement, and cognitive enrichment. Though a combined ENR approach has
not been explored in other animal models, individual aspects of ENR have been
studied. In rodents, exercise leads to increased brain derived neurotropic factor
and improved learning (80). However, the effects of ENR on transgenic mouse
models of AD have shown significant variability between studies (17, 202, 239). In
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people, individuals who live behaviorally enriched lifestyles, which includes
exercising or participation in activities that involve information processing, tend to
show less brain atrophy with age and exhibit reduced risk of dementia (70, 71,
485).
As discussed in Chapter 3, behavioral enrichment (ENR) in the canine model
of aging has been evaluated. In a study of aged canines, ENR included increased
exercise, interaction with other dogs, and cognitive enrichment. In 2004 and 2005,
Milgram and colleagues found ENR of aged canines to decrease the rate of
cognitive decline and improve cognitive function (278, 279).
A Combination Approach to Improve Cognition and Reduce Pathology in the
Canine Model of AD
Immunotherapy decreases Aβ pathology in humans and AD animal models,
while ENR improves overall cognition, growth factor levels and supporting neuron
number with varying Aβ outcomes.(116, 278, 279, 407). These results suggest
the exploration of a combination treatment approach with the potential for additive
effects to improve brain function and health with age. This study evaluates the
combination approach of active Aβ vaccination and behavioral enrichment by
examining their effects on cognition and neuropathology. We hypothesize that
additive benefits of improved cognition with reduced AD like pathology will be
exhibited in treated aged canines receiving a combination treatment approach of
active immunization with fibrillar Aβ1-42 using aluminum hydroxide (ALUM) as an
adjuvant (VAC) with ENR.
Copyright © Paulina R. Davis 2014
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CHAPTER FIVE: Methodology
Canines
The study was started with 40 beagles with 37 animals from the Lovelace
Respiratory Research Institute (LRRI) (Albuquerque, NM) and 3 from Harlan
(Riglan Farms, Inc., Mount Horeb, Wisconsin) (Table 5.1).

All animals were

reproductively intact. At the start of baseline, the ages of the dogs ranged from
10.5 to 13.6 years. At this age range, all study animals should have significant
prefrontal Aβ pathology (168). Animals were housed singly in kennel buildings
with indoor/outdoor runs measuring 91cm x 600cm, unless otherwise noted as part
of the ENR treatment. Animals were fed Harlan Teklad Global Diet (25% protein –
Teklad Pioneer Lab Diets, Madison, WI) once daily. Water was available for the
animals at all times. All animals were given a thorough veterinary examination to
assure they were in good health before inclusion in the study. Examinations
included physical examination, neurological examination, and analysis of blood
biochemistry. All procedures done with the animals were conducted in accordance
with LRRI-approved animal protocols and the National Institutes of Health Policy
on Humane Care and Use of Laboratory Animals.
Testing Apparatus
As described previously (277), the testing apparatus was a 0.609 X 1.15 X
1.08 m wooden box constructed from press board coated with melamine. The box
contained a sliding black Plexiglas tray containing three food wells. Adjustable
vertical stainless steel bars provided openings appropriate for individual dog sized
and made up the front of the box. The bottom of the barrier opened up so that a
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sliding tray would be able to be pushed either toward or out-of-view of the dog. A
60W light was placed above the presentation tray to light the objects.

Data

acquisition was controlled by a customized program, DOGMA (MetaCog Testing
Systems, New Westminster, BC).

This program controlled randomization

procedures and timing, indicated the placement of the reward, and stored all of
data. Each trial began when an experimenter pressed a key and the program
would provide an audio cue to present the tray to the dog. The dog’s response
would be recorded by identifying the location (left, right, or center) on the keyboard
or by a mouse. This also indicated the end of the trial and began an intertrial
interval. One teaspoon of wet dog food was formed into a ball and served as the
food reward. Each dog was given either 10 or 12 trials a day (depending on the
task). The dogs were tested 5 day a week.
Baseline Cognitive Testing
All dogs underwent a series of baseline tests and error scores during this
testing were used to counterbalance placement into treatment groups such that
each group contained both good and poor performers. All animals were given a
reward and object approach learning task and then a simple object discrimination
and reversal learning task. After discrimination learning, dogs were given a spatial
non-matching-to-position memory task. All tasks were performed as described in
Chapter 3, Dog Model. After placement into treatment groups, VAC and ENR
protocols were started, and cognitive testing was conducted for 19 months while
treatment was ongoing.
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Treatment Groups
The total errors made by each dog during baseline testing were summed and
used to rank animals according to total error scores. These cognitive test scored
were used to place animals into one of four treatment groups, making sure that
groups were balanced by baseline performance and age. These treatment groups
included (1) immunization with Alum only (n = 8) (C/C), (2) ENR with immunization
with Alum only (n = 8) (E/C), (3) immunization with fibrillar Aβ1-42 and Alum (n = 8)
(C/V), or (4) ENR with immunization with fibrillar Aβ 1-42 and Alum (n = 10) (E/V)
(Table 5.2).
Behavioral Enrichment Procedure
Dogs receiving ENR (groups E/C and B/V) were given a 20 min walk outdoors
in groups of 3-4 animals three times a week. Play toys were rotated through their
kennels on a weekly basis. ENR animals received cognitive enrichment involving
additional testing procedures including: landmark discrimination learning, variable
distance landmark discrimination, oddity discrimination learning and a second retest on landmark discrimination after ~16 months of treatment. For these cognitive
tasks, only dogs receiving ENR were included however we were able to compare
VAC and non-VAC dogs on each measure (Table 5.3).
Immunization Procedure
Fibrillar Aβ (provided by Dr. Charles Glabe, University of California at Irvine)
was prepared by adding 500 µl of phosphate buffer solution (PBS), pH 7.5, to 0.5
mg of peptide, and the sample was vortexed and incubated overnight at 37°C in a
water bath before formulation with the adjuvant. To prepare Aβ for immunization,

53

0.5 mg of fibrillar Aβ (500 µl) was added to 50 µl of 2% aluminum hydroxide
suspension (Accurate Chemical, Westbury, NY) and 450 µl of PBS and vortexed.
Animals in the C/C and E/C groups received Alum only. Animals were immunized
subcutaneously in the back of the neck and monitored for adverse reaction.
Animals were boosted every month with an additional single injection for 18
months.
Treatment Cognitive Testing
At predetermined time points during the study, animals were given tests to
measure spatial attention (landmark discrimination learning), spatial memory
(three-choice spatial testing), oddity learning, discrimination learning, and reversal
learning (black/white discrimination and size discrimination) (Table 5.3). All tasks
were performed as described in Chapter 1, Dog Model.
Serum and CSF Collection
Blood samples were obtained at baseline, taken immediately before the first
immunization to obtain a pre-immune sample, monthly for six months, and then
every six months thereafter. Blood was collected in 10 cc collection tubes and
centrifuged, and the supernatant (serum) used to assay anti-Aβ antibodies.
Serum samples were thawed, aliquoted, and frozen again at -80°C for later use.
Cerebral spinal fluid (CSF) was collect from each animal at the start of the study
before the first immunization (baseline), 12 months after start of treatment, and at
the time of euthanasia. CSF was drawn from the lateral ventricles, aliquoted,
frozen, and were stored at -80°C for later use.
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Euthanasia and Tissue Collection
At the end of the study, animals were anesthetized with sodium pentobarbital
(Nembutal). Blood was collected in 10 cc red top tubes and centrifuged, and the
supernatant (serum) used to assay anti-Aβ antibodies. When animals were in
deep surgical stage, the brains were rapidly removed. Procedures were performed
in accordance with LRRI Institutional Animal Care and Use Committee protocols.
The left hemisphere was placed in 4% paraformaldehyde at 4°C for48 hours before
transfer to PBS, pH 7.4 with 0.02% sodium azide and stored at 4°C. The right
hemisphere was coronally sectioned and stored at -80°C.
Serum IgG ELISA
Aβ1-42 antibody response was measured over nine time points of the study
by enzyme-linked immunosorbent assay (ELISA). 96 well flat bottom plates
(Microtiter Immunlon 2 HB, Fisher, cat# 14-245-61) were coated with 5µg/ml
fibrillar Aβ1-42 in 0.1M phosphate buffered saline (PBS) (pH 7.5) and incubated
overnight at 4°C. Blank wells received PBS only. After incubation, plates were
washed three times in Tris buffered saline with 0.05% Tween-20 (TBST) (pH 7.5).
Plates were then blocked with blocking buffer (TBST with 3% bovine serum
albumin (BSA)) and incubated for two hours at 37° on a plate rocker. Plates that
were not used immediately after blocking were stored at 4°C until needed. Once
blocked, plates were washed three times in TBST. Serum samples being used
were serially diluted in 1:10 dilution of blocking buffer (0.3% BSA in 2mM TBST)
to 1:100, 1:400. 1:800, and 1:1600. Antibody 6E10 (Aβ 1-16, Covance, Dedham,
MA; cat# SIG-39320) was used for standards and serially diluted to 1:10,000,
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1:20,000, 1:40,000, 1:80,000, 1:160,000, and 1:320,000. Wells received 100µl of
each sample, 6E10 antibody, or PBS. For a positive control and serum only control
wells, 100 µl of 6E10 at 1:10,000 dilution and 1:200 dilution of sample was added,
respectively. Plates were incubated for one hour at 37°C on a plate rocker. After
three washes in TBST, 100 µl of horseradish peroxidase (HRP) conjugated
secondary antibody diluted in blocking buffer was added to each well. Canine
sample wells received anti-dog IgG-HRP (Bethyl Laboratories, Montgomery, TX;
cat# A40-116P) as secondary, while standard and control wells received antimouse IgG-HRP (Santa Cruz Biotechnology, Santa Cruz, CA; cat# SC-2005).
Plates were incubated with secondary antibody for one hour at 37°C on a plate
rocker.

Following three washes in TBST, 100µl of 1 Step Ultra 3, 3’,5,5’-

tetramethylbenzidine solution (TMB) (Thermo Scientific, cat# 34028) (room
temperature) was added to each well to start the reaction. TMB reaction was held
for 3 minutes and then stopped by adding 100µl of 1N sulfuric acid. After 5 minutes
when reaction has completely stopped, plates were read at 450 nm using a
Multiscan FC plate reader (Thermo Scientific).
Frozen Tissue Extractions
Frozen tissue underwent a basic three step serial extraction before being
used to measure Aβ content. Tissue first went through a phosphate buffered saline
(PBS) extraction. 200mg of tissue was homogenized in 1 mL of 4° 1x PBS with
complete protease inhibitor cocktail (PIC; with EDTA; Amresco, Solon, OH, cat#
M222-1mL) (pH 7.4). Homogenization was done using a polytron at maximum
speed. Raw homogenate was added into 1.5 mL centrifuge tubes and centrifuged
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at 20,000 x g for 30 minutes at 4°C. Supernatant was collected and stored at 80°C while the pellet was saved and used for the following extraction by sodium
dodecyl sulfate (SDS). Here, room temperature 2% SDS with PIC (in water) was
added to the PBS pellets. The total volume of 2% SDS added to the PBS pellet
was determined by calculating 70% the volume of PBS raw homogenate. Samples
were sonicated with 10x 0.5 second pulses with an amplitude of 20% (Fisher sonic
Dismembrator, Model 500). Samples were centrifuged at the same conditions as
stated earlier. Supernatant was collected and stored while the pellet was used for
the following Formic Acid extraction. For the last extraction by formic acid, samples
were diluted 1:40. First samples were diluted 1:20 in neutralization buffer (Tris
Phosphate Buffer) followed by a 1:1 dilution in antigen capture (AC) buffer (0.02M
sodium phosphate buffer (pH=7), 0.4M NaCl, 0.02 M EDTA, 0.4% Block Ace
(Serotec, Raleigh, NC), 0.2% BSA, 0.05% CHAPS, and 0.05% NaN3). Add 4°
equal volume of 70% formic acid as that of SDS added to the PBS pellets to the
SDS pellets.

Samples were sonicated with 10x 0.5 second pulses with an

amplitude of 20% and centrifuged at 20,000 x g for 30 minutes at 4°C. The
underlying aqueous layer was collected and stored at -80°C for later use.
CSF and Brain Aβ ELISAs
Beta-amyloid (1-40, 1-42, and total) was measured in CSF and tissue by sandwich
ELISA. Capture antibodies Ab42.5 (human sequence Aβ 1-16) for Aβ1-40 capture,
and 2.1.3 (end specific for Aβ1-42) were diluted to 10 µg/mL in PBS and added
(50µL) to each well of a 384 well plate (Immulon, cat# 4HBX). Any unused wells
were filled with 50 µL of PBS. Once loaded, plates were sealed with sealing tape
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and incubated overnight at 4°C. Plates were then emptied and rinsed with 1X
PBS. To block the plates, 100µL of Synblock (Serotec, cat# BUFO34C) was added
to each well, sealed and incubated for 2 hours at room temperature on a plate
rocker. Once blocked, plates were emptied and dried for two hours at room
temperature. Plates not used the same day could be sealed and stored at 4° in a
dessicator for later use. Before antigen capture, plates were washed twice in 1X
PBS. Samples were then added (100µL) in triplicate and then plates were sealed
and incubated overnight at 4°C. Fluid from wells was discarded and washed twice
with 1X PBS and 1X PBST. Next, 100µL of biotinylated detection antibodies
biotinylated 13.1.1 (end specific for Aβ1-40, and biotinylated 4G8 (human sequence
Aβ17-24, Covance) diluted in detection buffer (DB) (0.02M sodium phosphate buffer
(pH=7), 0.002% Thimerosal, 0.002M EDTA, 0.4M NaCl, and 1% BSA) was added
to the plates, sealed, and incubated at room temperature for four to six hours.
Following an incubation in detection antibody, plates were emptied, washed, and
filled with 100µL of NeutrAvidin-horse radish peroxidase (Pierce Biotechnologies,
Rockford, IL) diluted in DB. After incubating for two hours at room temperature,
solution was discarded and plates were washed several times. For developing, a
1:1 mixture of TMB developing solution (Kirkegaard and Perry Laboratories,
Gaithersburg, MD) was made and added (100µL) to each well and allow to
incubate for about five minutes. Developing reaction was stopped by adding
100µL of stop buffer (5.6% O-Phosphoric Acid) to the wells and then plates were
read with a BioTek multiwell plate reader at λ450nm. Total levels of Aβ 1-40 and Aβ1-
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42

were determined by calculating the sum of levels in each fraction (PBS, SDS,

and FA).
Plaque Load IHC
Tissue was stained for Aβ plaques by using anti-Aβ1-42 (Invitrogen, Carlsbad, CA;
cat# 44-344; 1:500), 6E10 (Covance, Dedham, MA; cat# SIG-39320; 1:1000), and
PyroGlu3 (Novus Biological, Littleton, CO; cat# NBP1-44048; 1:500) (Table 5.4)
antibodies. Tissue was pre-treated in 90% formic acid for 4 min and washed in
Tris-buffered saline (TBS) (pH 7.5). Next, a 30 min treatment in 3% hydrogen
peroxide and 10% methanol was done to block endogenous peroxidase activity.
After two washes in TBS, sections were then washed in TBS with 0.1% Triton X100 (Sigma X-100) and blocked in TBS with 0.1% Triton X-100 and 2% Bovine
serum albumin for 30 min to block non-specific sites.

Sections were then

incubated with primary antibody overnight at room temperature. Following the
primary antibody the tissue was incubated in biotinylated secondary antibody for
rabbit or mouse (Vectastain Elite ABC kit, Vector Laboratories, Burlingame, CA;
cat# PK-6101 (rabbit), PK-6102 (mouse)). After several washes sections were
incubated for one hour in an avidin-biotin complex (Vectastain Elite ABC kit, Vector
Laboratories, Burlingame, CA; cat# PK6101). Detection was visualized with 3’diaminobenzidine and hydrogen peroxide (DAB, Vector Labs, Burlington, CA; cat#
SK4100). Sections were mounted on Superfrost/Plus slides (Labsco Scientific
America, cat# LSA4951), left to dry, dehydrated, and coverslipped with 66m glass
coverslips (Labsco Scientific America, cat# LS529J) using Depex mounting media
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(Electron Microscopy Sciences, cat# 13515).

Appropriate controls included

sections eliminating primary or secondary antibodies, and all were negative.
Prussian Blue Staining
Prussian blue staining was used to identify microhemorrhages in PFCTX, OCTX,
and Hippo tissue for all study cases. With this stain, only iron from hemosiderin
containing microglia in the extracellular matrix is colorized (indicative of
microhemorrhages).

Prior to staining, tissue was mounted onto Labsco

Superfrost/Plus slides and air dried overnight. Slides were rehydrated in distilled
water for 30 seconds and then incubated in 2% potassium ferrocyanide with 2%
6N concentrated HCl (made in distilled water) for 30 minutes. After incubation,
slides were rinsed twice in distilled water for five minutes each and then once in
tap water for another five minutes. Once rinsed, slides were incubated in filtered
1% neutral red solution (J.T. Baker, cat# R746-03) (mixed overnight) for two
minutes. Tissue was rinsed three times in tap water for 1 minute each, and
dehydrated by dipping slides four times in 95% ethanol and four times in 100%
ethanol. Slides were cleared twice in xylene for five minutes each and then
coverslipped with Depex mounting media.
Baseline Comparison for Plaque Load and Prussian Blue
We

were

interested

in

estimating

the

extent

of

Aβ

pathology

and

microhemorrhages in our dogs prior to the start of treatment to characterize
changes in pathology over time and with immunotherapy/behavioral enrichment.
We selected 10 archive cases (Table 5.5) that ranged in age from 10.8 to 13.5
years to compare changes in plaque loads and number of microhemorrhages
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before treatment to after 19 months of treatment, particularly with ENR study
animals. These archive cases had no previous treatment or cognitive testing done.
Tissue for archive cases were collected using the same methods as the study
cases.
Immunohistochemistry was used to measure total Aβ, Aβ1-42, and PyroGlu3 plaque
loads in the PFCTX and PCTX and was conducted in the same manner as with
study case tissue. Prussian Blue staining was used to count the number of
microhemorrhages in the PFCT and OCTX regions of the brain and was done in
the same manner as with study case tissue.
Image Analysis for Plaque Load and Prussian Blue
To quantify the extent of Aβ plaque labeling, images were captured using
ImagePro 6.3 with an Olympus Q-Color 5 camera on an Olympus BX51
microscope at 20x objective uniformly, five of the superficial layers and five of the
deep layer. Quantification was done by image analysis using ImageJ to yield load
values, the percent area occupied by positive labeling (Figure 5.1). A threshold
was identified for each antibody/marker and applied to calculate a total average
load of each image. The loads of all 10 images were averaged for each subject.
These subject averages were then used to find a treatment group average for
treatment group comparisons.
Quantification

of

Prussian

blue

staining

entailed

manually

counting

microhemorrhages in each tissue sample at 20X objective. Prussian blue labeling
must have been within 2 cell diameters of a blood vessel to be considered a
microhemorrhage (Figure 5.2). Counts were totaled for each subject in each brain
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region. For each brain region subject averages were used to calculate a treatment
group average to be used for treatment group comparisons.
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Table 5.1. Dogs used in the Study
Dog ID

Sex

Date of Birth

Baseline
Date

Age at
Baseline (mo)

Date of
Death

Age at
Death
(mo)

1625A
1625C
1628A
1628C
1633D
1633S
1635A
1635S
1635T
1636V
1637B
1637T
1638U
1639B
1639C
1639T
1639W
1640B
1640C
1640S
1640U
1640V
1640W
1641A
1641B
1641T
1641U
1641V
1642A
1642B
1642S
1643C
1643T
1645A
1645T
1646T
1646U
D009
D012
D045

M
M
M
M
M
F
M
F
F
F
M
F
F
M
M
F
F
M
M
F
F
F
F
M
M
F
F
F
M
M
F
M
F
M
F
F
F
M
F
F

9/16/1997
9/16/1997
1/3/1998
1/3/1998
4/27/1998
4/27/1998
6/9/1998
6/9/1998
9/8/1998
6/28/1998
8/21/1998
7/29/1998
8/20/1998
8/21/1998
8/21/1998
8/21/1998
8/20/1998
9/8/1998
9/8/1998
9/8/1998
9/8/1998
9/8/1998
9/12/1998
9/12/1998
9/12/1998
9/12/1998
9/8/1998
9/12/1998
7/24/1999
7/24/1999
7/24/1999
7/24/1999
7/26/1999
8/10/1999
8/10/1999
10/16/1999
10/16/1999
12/8/1996
11/12/1996
9/15/1996

4/18/2010
4/18/2010
4/18/2010
4/18/2010
4/18/2010
4/18/2010
4/18/2010
4/18/2010
4/18/2010
4/18/2010
4/18/2010
4/18/2010
4/18/2010
4/18/2010
4/18/2010
4/18/2010
4/18/2010
4/18/2010
4/18/2010
4/18/2010
4/18/2010
4/18/2010
4/18/2010
4/18/2010
4/18/2010
4/18/2010
4/18/2010
4/18/2010
4/18/2010
4/18/2010
4/18/2010
4/18/2010
4/18/2010
4/18/2010
4/18/2010
4/18/2010
4/18/2010
4/18/2010
4/18/2010
4/18/2010

151.1
151.1
147.6
147.6
143.8
143.8
142.4
142.4
142.4
141.8
140.7
140.7
140
140
140
140
140
139.4
139.4
139.4
139.4
139.4
139.4
139.3
139.3
139.3
139.3
139.3
128.9
128.9
128.9
128.9
128.8
128.4
128.4
126.1
126.1
160.4
161.3
163.2

9/20/2010
7/23/2010
6/20/2012
6/18/2012
4/26/2012
6/20/2012
7/23/2010
2/26/2012
4/11/2012
6/7/2011
6/18/2012
6/19/2012
9/2/2010
6/19/2012
6/18/2012
6/18/2012
6/19/2012
6/19/2012
6/19/2012
5/17/2012
8/26/2011
4/18/2011
5/11/2012
6/20/2012
6/18/2012
8/22/2010
4/15/2011
6/18/2012
6/20/2012
6/20/2012
12/29/2011
7/2/2010
6/20/2012
6/20/2012
6/19/2012
6/18/2012
6/18/2012
7/9/2011
6/19/2012
6/19/2012

156.2
154.3
173.7
173.6
168.1
169.9
145.5
164.7
166.2
155.4
166.8
166.8
144.5
166.1
166
166
166.1
165.5
165.5
164.4
155.7
151.4
164.2
165.4
165.3
143.4
151.2
165.3
155
155
149.3
131.4
154.9
154.5
154.4
152.2
152.2
175.1
187.3
189.2
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Table 5.2. Treatment Group Assignments
Dog ID Treatment Group

Time on Treatment (mo)

1625A
1625C
1628A
1628C
1633D
1633S
1635A
1635S
1635T
1636V
1637B
1637T
1638U
1639B
1639C
1639T
1639W
1640B
1640C
1640S
1640U
1640V
1640W
1641A
1641B
1641T
1641U
1641V
1642A
1642B
1642S
1643C
1643T
1645A
1645T
1646T
1646U
D009
D012
D045

0
0
19.6
19.5
17.8
19.6
0
15.8
17.3
7.1
19.5
19.6
0
19.6
19.5
19.5
19.6
19.6
19.6
18.5
9.8
5.5
18.3
19.6
19.5
0
5.4
19.5
19.6
19.6
13.9
0
19.6
19.6
19.6
19.5
19.5
8.2
19.6
19.6

--C/C
C/C
E/V
E/C
-E/V
C/V
E/V
C/V
E/C
-E/V
C/V
C/C
C/C
E/V
C/C
C/V
E/C
E/C
C/C
E/C
E/C
-E/C
C/C
C/V
E/V
C/V
-C/V
E/V
E/V
E/V
C/C
E/C
C/V
E/V
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Table 5.3. Cognitive Testing Timeline
Time
Between Study
Boosts
Month

Study Event
Baseline
Serum and Plasma Time B1
Blood Biochemistry - Time B1

-6.0
-6.0

Physical and Neurological Examinations Time B1
Pretraining - Phase 1
Reward Approach Learning
Pretraining - Phase 3
Object Approach learning
Baseline CSF sample
Baseline - Object Discrimination Learning
Baseline - Object Reversal Learning
Baseline - 2 choice spatial learning
Baseline - 3 choice spatial learning
Baseline - 3 choice spatial memory
Blood Biochemistry - Time B2
Treatment
Serum and Plasma Imm 0
Immunization-1
Begin behavioral enrichment protoocol
Serum and Plasma Imm 2w
Immunization-2
Serum and Plasma Imm 1m
Immunization 3
Landmark Testing - Land0-Land4
Serum and Plasma Imm 2m
Immunization 4
Serum and Plasma Imm 3m
Immunization 5
Oddity Discrimination Learning
Serum and Plasma Imm 4m
Immunization 6
Serum and Plasma Imm 5m
Immunization 7
Physical and Neurological Examinations
Serum and Plasma Imm 6m
Immunization 8

-6.0
-6.0
-6.2
-6.2
-6.0
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-4.8
-4.6
-4.0
-3.7
-1.1
-0.7

0

14
14

28
28

28
28

28

0.7
0.7
0.7
1.2
1.2
1.6
1.7
1.7
2.6
2.6
3.5
3.5
4.2
4.5
4.5
5.4
5.4
6.1
6.3
6.3

Table 5.3, continued
Blood Biochemistry 6 m
Immunization 9
Immunization 10
Time 1 - Size Discrimination Learning
Time 1 - Size Reversal Learning
Immunization 11
Time 1 - Spatial Acquisition
Immunization 12
Immunization 13
Immunization 14
Blood Biochemistry 12m
Physical and Neurological Examinations
Serum and Plasma Imm 12m
CSF sample
Time 1 - Spatial Memory
Immunization 15
Immunization 16
Immunization 17
Immunization 18
Time 2 - Landmark Variable Distance Retest
Immunization 19
Time 2 - Black/White Discrimination Learning
Immunization 20
Blood Biochemistry 18m
Serum and Plasma Imm 18m
Time 2 - Black/White Reversal Learning
Physical and Neurological Examinations
Immunization 21
Time 2 - Spatial Memory
Immunization 22
BrdU injections once daily for 5 days
Immunization 23
Serum and Plasma Imm 23m
Blood Biochemistry 24m
CSF sample immediately prior to euthanasia
Euthanasia
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28
28

28
28
28
28

28
28
28
28
28
28

28
28
28

6.3
7.3
8.2
8.4
8.9
9.1
10.0
10.1
11.0
11.9
11.9
11.9
11.9
12.1
12.4
12.9
13.8
14.7
15.7
16.1
16.6
17.0
17.5
17.5
17.5
17.7
18.2
18.5
19.1
19.4
20.1
20.3
20.5
20.5
20.5
20.5

Table 5.4. Antibodies used for Immunohistochemistry
Antibody Name
Target
Dilution
Secondary Manufacturer
Aβ 1-42
6E10
PyroGlu3

Aβ (42)
Aβ (1-16)
Aβ (3 pE)

1:500
1:1000
1:500

Rabbit
Mouse
Mouse
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Invitrogen
Covance
Novus Biological

Table 5.5. Pre-Treatment Dogs used in the study
Dog ID Sex Date of Birth
Date of Death

Age at Death (mo)

1425S

F

11/26/1983

6/3/1997

162.4

1470S
1485V
1509S
1580S
1634U
1634V
1639U
1639V
D304

F
F
F
F
F
F
F
F
F

1/22/1986
12/1/1986
3/2/1988
5/15/1991
6/7/1998
6/7/1998
8/21/1998
8/21/1998
7/30/1991

6/11/1997
4/1/1999
12/18/1998
12/11/2002
1/29/2010
4/7/2009
4/6/2010
2/17/2010
12/23/2002

136.7
148.1
129.6
139.0
139.9
130.1
139.6
138.0
136.9
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Figure 5.1. Quantification of Aβ Plaque loads.
Black and white image taken of 6E10 labeled tissue (A) and the same capture
that has been thresholded so that only positive labeling is seen in black (B). This
threshold is used to obtain a measure of total area occupied by positive labeling
for 6E10.
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Figure 5.2. MHs in the FCTX of AD and aged canine.
Aged canines show MHs just as seen in aged humans. Arrows point to MHs
in FCTX tissue stained with Prussian Blue of a human with AD (A) and of an aged
canine PFCTX (B).

Arrowheads point to blood vessel associated with each

neighboring MH. Bleed labeling must have been within 2 cell diameters of a blood
vessel to be considered a microhemorrhage.
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CHAPTER SIX: Results
Cognitive Outcomes
Landmark Discrimination Learning
All dogs receiving ENR were given the landmark discrimination task. Thus, a
comparison between dogs receiving the vaccine could be compared to those not
receiving the vaccine, with all dogs being behaviorally enriched. Testing began 1
month after the first vaccination and 2 weeks after the first boost.
In the 18 (n=10 E/V, n=8 C/V) dogs that completed landmark 0, a significantly
higher error score was observed in the dogs provided with the vaccine relative to
the dogs receiving behavioral enrichment alone (t(16)=2.7 p=0.016)(Figure 6.1).
However, based on our previous research, rather than the vaccinated dogs doing
more poorly, this effect is due to significantly lower error scores in all dogs that was
pronounced in the E/C group when compared to previous studies of similarly aged
dogs (276). In landmark 1 discrimination learning, no significant group effects were
observed (t(16)=1.45 p=0.17). Interestingly, in landmark 1 learning, two of the
vaccinated dogs made over 100 errors to learn the task whereas the average error
scores for the E/C condition was 9.88+/-4.74 and for the remaining dogs on E/V
condition averaging 5.0 +/- 1.46 errors. Scores of over 100 errors are typical of
untreated aged animals as previously reported (275, 276). A differential vaccine
effect was also not observed for landmark 2 (2 cm distance) (t(14)<1 p=0.77) or
landmark 4 (4 cm distance) (t(14)<1 p=0.48). A similar outcome was noted if a
repeated measures general linear models approach is used to detect differential
effects of the vaccine across all landmark tasks although the effect of distance on
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error scores overall was significant (F(3,42)=2.8 p=0.05) suggesting the further
distances resulted in higher error scores reflecting increasing difficulty of the task
(Figure 6.1).
The variable distance landmark test was conducted for a period of 20 days
with either 1, 2 or 4 cm distances appearing each day, four times/day for a total of
12 trials/day. The total number of errors made during the 20 days of testing was
not different between the E/V nor E/C groups (t(13)<1 p=0.53). Next, the accuracy
was calculated for individual distances for each dog as further distances are more
difficult for animals to detect proximity to the correct response. All dogs performed
between 62-72% correct with little variability across distances. A repeated
measures general linear models analysis confirmed a lack of main effect of
distance (F(2,24)=2.2 p=0.133) and of treatment group (F(1,12)<1 p=0.53). The
interaction, was also not significant (F1,12)< 1 p=0.78) (Figure 6.2).

This is

contrast to previous reports of the variable distance landmark task varying as a
function of distance (177).
After 15.2 months of treatment, 4 E/C and 8 E/V dogs were given a second
assessment of the landmark variable distance task for 240 trials. There was a
significant effect of distance of the landmark and error scores such that longer
distances led to greater numbers of errors (F(2,20)=12.90 p=<.0005). There were
no differences between the group receiving the vaccine (E/V) and the control group
(E/C) or an interaction between distance and treatment condition (data not shown).
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Oddity Discrimination Learning
A comparison was made between the 8 vaccinated (E/V) vs 10 nonvaccinated (E/C) dogs on the oddity task after 4.3 months of treatment with all dogs
having behavioral enrichment. When individual oddity problems were analyzed
using t-tests to compare the two groups we did not see any significant differences.
For oddity 1, 7 E/C dogs and 9 E/V dogs reached criterion levels of responding
(t(14)<1 p=n.s.). For oddity 2, 7 E/C dogs and 9 E/V dogs learned the task
(t(14)=1.40 p=0.18). For oddity 3, 6 E/C dogs and 9 E/V dogs learned but no
significant differences were observed (t(13)<1 p=n.s.). Last, for oddity 4, 6 E/C
dogs and 9 E/V dogs learned but error scores were similar (t(13)=1.37 p=0.20). In
a second repeated measures analysis (4 oddity tasks) using only dogs that were
able to reach criterion levels of responding on all tasks, the two groups (E/C vs
E/V) were compared. There was a significant main effect of the oddity task
(3,39)=4.75 p=0.006) suggesting increasing difficulty, but no treatment group by
oddity task interaction (F(3,39)=0.39 p=0.76). Overall there were no treatment
group differences (F(1,13)=3.41 p=0.088)(data not shown).
Discrimination and Reversal Learning
After 7.6 months of treatment, all dogs were given a size discrimination and
reversal learning problem. This task allowed us to compare all 4 treatment groups
and test the hypothesis that the combined treatment led to greater cognitive
benefits than either treatment alone and as compared to controls. All dogs still on
study learned the size discrimination problem. Using a univariate analysis of
variance (behavioral enrichment, vaccine), there was no significant effect of the
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vaccine alone (F(1,30)<1 p=n.s.), the behavioral enrichment alone (F(1,30)=0.36
p=0.55) nor the interaction of the two treatments (F(1,30)<1 p=n.s.).

For size

reversal learning, 28 dogs in total learned the task. No significant improvements
in the vaccine group alone (F(1,28)=0.33 p=0.57), the behavioral enrichment group
alone (F(1,28)=0.98 p=0.33) nor in the combination group (F(1,30)=0.029 p=0.87)
was observed (data not shown).
We next compared baseline levels of discrimination and reversal learning to
size discrimination learning to determine if there was a maintenance of function in
treated animals. In this repeated measures analysis, we observed a significant
effect of time (or of task difficulty) between baseline discrimination learning and
size discrimination learning (F(1,26)=10.74 p=0.003) with error scores being
higher on the size task. No group differences nor a group by time interaction was
observed suggesting no treatment effects on the maintenance of discrimination
learning (data not shown). Similarly for reversal learning, there was a significant
effect of time (or of task difficulty) overall (F(1,24)=17.1 p<.0005) with size reversal
leading to higher error scores but no main effects of each treatment nor a time by
group interaction (data not shown).
After 16.1 months of treatment, all dogs on the study were given the final
discrimination learning and reversal tasks, black/white discrimination and
black/white reversal learning. On the black/white discrimination learning task, 7
C/C, 4 E/C, 3 C/V and 7 E/V animals were able to reach criterion. There was no
main effect of the vaccine (F(1,21) = 1.49 p=0.24), the behavioral enrichment
(F(1,21)=0.07 p=0.80) nor a significant combination treatment effect (F(1,21)=0.12
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p=0.73) (data not shown). Similarly, of the 6 C/C, 4 E/C, 3 C/V and 6 E/V dogs
able to reach criterion on the black/white reversal learning task, no main effect of
the vaccine (F(1,19)=0.32 p=0.58), of the behavioral enrichment (F(1,19)=0.79
p=0.40) nor of the combination treatment (F(1,19)=3.26 p=0.09) was observed
(data not shown).
To detect any treatment effects over time (i.e. a possible maintenance of
function) we compared baseline object discrimination to size discrimination and to
black/white discrimination only in animals able to reach criterion for all 3 tasks.
Overall there was a significant increase in error scores over time in all groups
(F(2,32)=3.4 p=0.05) suggesting both an aging effect and an increase in task
difficulty but no effect of the vaccine (F(2,32)=0.11 p=0.90) or of the behavioral
enrichment alone (F(2, 32) =0.56 p=0.58). Interestingly, there was a significant
effect of the combination treatment group (F(2, 32)=4.0 p=0.03) and as can be
seen in Figure 6.3A, the combination group had the lowest average error scores.
Reversal learning also showed a significant main effect of time in dogs that could
learn the problem (F(2,30)=10.7 p<.0005) but there were no main effects of the
vaccine alone (F(2,30)=2.8 p=0.08) or the behavioral enrichment alone
(F(2,30)=0.09 p=0.91) nor of the combination treatment (F(2,30)=1.12 p=0.34) on
change in error scores over time (Figure 6.3B). Interestingly, as can be seen in
Figure 6.3B, the E/V group had the highest average error scores on reversal
learning, whereas the two single treatment groups showed lower error scores.
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Spatial Acquisition and Memory
Once dogs had been treated for 9.4 months, they were retested on the 3
choice spatial memory problems. At this time, dogs were given 50 days maximum
to sequentially re-acquire the task at progressively increasing delays beginning
with a 5 second delay. A multivariate analysis of variance was used to determine
whether group differences were present with the initial re-learning at a 5 second
delay. In this analysis, 7 C/C dogs, 4 E/C dogs, 7 C/V dogs and 7 E/V dogs
reached criterion levels of responding. No significant main effects of the vaccine
(F(1,25)=0.577 p=0.46), of behavioral enrichment (F(1,25)=1.83 p=0.19) nor of the
combined treatment (F(12,25)=0.039 p=0.85) was observed (data not shown).
At the end of spatial acquisition testing, dogs were given a variable spatial
memory task where the delays of 20, 70 or 110 seconds could occur on a single
day. On this phase of the test, 8 C/C, 4 E/C, 8 C/V and 8 E/V dogs completed all
240 trials. The main effect of the delay interval on accuracy was marginally
significant (F(2,48)=2.91 p=0.06) but no delay by vaccine group (F(2,48)=0.71
p=0.50), no delay by behavioral enrichment group (F(2,48)=1.11 p=0.34) nor a
delay by vaccine group by behavioral group interaction (F(2,48)=1.26 p=0.29) was
found. Thus, neither treatment alone or in combination resulted in improved spatial
memory (Figure 6.4A and B).
A third and final test of spatial memory alone (without the acquisition phase)
was initiated after 18.1 months of treatment. For this test, 8 C/C, 4 E/C, 5 C/V and
6 E/V dogs remained on study. The overall effect of delay on accuracy was blunted
in this last test (F(2,38)=2.85 p=.07) most likely due to the smaller sample size.
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There was no delay by vaccine group effect (F(2,38)=0.72 p=0.49) or delay by
behavioral enrichment group effect (F(2,38)=0.31 p=0.74). Interestingly, there was
an interaction between the delay interval accuracy in the combination treatment
group (F(2,38)=3.62 p=0.04). Figure 6.4C shows that this was primarily due to the
poorer performance of the E/C and C/V groups at the short 20 second delay
whereas the C/C and E/V groups showed a progressive decline in accuracy from
20 to 110 seconds delays.
To detect any changes in spatial memory as a function of treatment over the
18 months of the study, a repeated measures analysis was used for each delay
interval separately (20,70,110s). At the 20 second delay (F(2,36)=16.12 p<.0005),
the 70 second delay (F(2,36)=5.51 p=0.008) and the 110 second delay
(F(2,36)=17.32 p<.0005) there was an overall decrease in accuracy over time
suggesting an aging effect. There was no apparent maintenance of spatial memory
over time as a function of treatment (Figure 6.4 D, E, F).
IgG Anti-fibrillar Aβ Antibody Response in Serum
To determine if the anti-fibrillar Aβ given to VAC treated animals induced an
immune response, we measured fibrillar Aβ1-42 antibody titers (Figure 6.5). Past
active vaccine studies showed an increase in Aβ antibody titers in treated animals
(177).

Therefore, we hypothesized the C/V and E/V groups would have an

increase in Aβ antibody titers over time. At baseline, there were low and variable
levels of anti-Aβ titers in serum across dogs. Thus, to reduce individual variability
of measurements due to baseline titers and to allow comparisons across groups
over time, the difference between each time point measure of anti-Aβ titers from
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baseline was calculated. Similar to previous studies, fibrillar Aβ antibody titers
significantly increased over time in VAC animals (F(1,19)=12.5 p=0.002) (Figure
6.5A). No main effect of behavioral enrichment was seen on antibody titers
(F(1,19)=1.16 p=0.30).

Further, there was no interaction between the two

treatments (F(1,19)=1.32 p=0.26).

While antibody titers in the combination

treatment group did increase over time, as can be seen in Figure 6.5B, the
maximum response did not reach that of the vaccine only group (Figure 6.5A). Post
hoc tests show that at time 23 months the combination group had lower titers
(p=0.018, LSD).

Additionally, the antibody titer response in the combination

treatment group was delayed about 2 months (Figure 6.5A).
CSF Aβ
CSF Aβ levels are lower in AD compared with non-demented elderly controls
as Aβ from the periphery deposits in the brain decreasing CSF Aβ and increasing
brain Aβ and cognitive impairment (for review, see (14)). In animal studies, mice
receiving passive immunization with antibodies against soluble Aβ experience an
increase in CSF Aβ (100).

Additionally, dogs receiving active vaccination

experienced a non-significant increase in CSF Aβ1-40 and decrease in Aβ1-42 (165).
We hypothesized that CSF Aβ levels would be higher in the C/V and E/V treatment
groups compared to the C/C and E/C groups as a result of the VAC. CSF Aβ 1-40
and Aβ1-42 were measured by sandwich ELISA. A significant increase in CSF Aβ140

levels was seen in response to ENR (F(1,22)=5.76 p=0.03) (Figure 6.6A), while

there was no effect of the vaccine (F(1,22)=0.41 p=0.53) (Figure 6.6B) or an
interaction between the two treatments (F(1,22)=1.16 p=0.29) (Figure 6.7).
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Though not significant, the E/V treatment group trended towards having the largest
impact in increasing CSF Aβ1-40 compared to all other treatment groups (Figure
6.7). No treatment effect was seen for ENR (F(1,22)=0.38 p=0.54) alone for Aβ 142

(Figure 6.8A). VAC had no treatment effect in lowering or raising CSF Aβ 1-42

over time (F(1,22)=0.40 p=0.40), but VAC animals did have significantly higher
levels than non-VAC animals at 12 months (F(1,22)=8.089 p=0.008) (Figure 6.8B).
Last, there was also no interaction treatment effect on CSF Aβ 1-42 for the two
treatments over time (F(1,22)=0.06 p=0.81) (Figure 6.9).
Aβ Plaque Load
Based on the previous canine vaccine study indicating that Aβ plaque loads
were decreased due to VAC, we hypothesized that animals from the C/V and E/V
treatment groups would have decreased Aβ plaque loads compared to non VAC
animals (177). We also hypothesized that the E/V group would have a greater
reduction in plaque load than the C/V group as an effect of the combination
treatment approach. To test this hypothesis we measured the extent of plaques
containing Aβ1-42, total Aβ, and pyroglutamate Aβ in the PFCTX, OCTX, PCTX,
and ECTX by immunohistochemistry.
Aβ1-42
Aβ1-42 plaque load was measured in the PFCTX, OCTX, PCTX, and ECTX in
all animals and compared between treatments. Plaque load was significantly
decreased as a result of VAC (both C/V and E/V groups) in the PFCTX (F(1, 34)=
33.04 p= <0.001), OCTX (F(1, 34)= 14.92 p= 0.001), and PCTX (F(1, 33)= 14.06
p= 0.001), while no reduction was seen in the entorhinal cortex (ECTX) (F(1, 34)=
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1.89 p= 0.39) (Figure 6.10). Compared to the C/C group, the C/V group showed
a significantly lower Aβ1-42 plaque load in the PFCTX (Bonferroni, p=<0.001),
OCTX (Bonferroni, p=0.04), and PCTX (Bonferroni, p=0.02) (Figure 6.10).
However there was no significant difference between the C/C and C/V groups
when comparing plaque loads in the ECTX (Bonferroni, p=1.00) (Figure 6.10). No
significant reduction in Aβ1-42 plaque load was seen as an effect of ENR in the
OCTX

(F(1,34)=0.19

p=0.67),

PCTX

(F(1,33)=2.21

p=0.15),

or

ECTX

(F(1,34)=0.754 p=0.39) (Figure 6.10). However, a reduction in the PFCTX due to
ENR trended towards significance (F(1,34)=3.87 p=0.06) (Figure 6.10). Similarly,
when looking at individual treatment groups, the E/C group had a significantly
lower plaque load compared to the C/C group in the PFCTX (Bonferroni, p=0.02),
while no difference was seen in the OCTX (Bonferroni, p=1.00), PCTX (Bonferroni,
p=0.55), or ECTX (Bonferroni, p=1.00) (Figure 6.10). No additive effects were
seen between the VAC and ENR in reducing Aβ 1-42 plaque load in the OCTX
(F(1,34)=0.14 p=0.71), PCTX (F(1,33)=1.18 p=0.29), or ECTX (F(1,34)=0.18
p=0.68) (Figure 6.10). Statistically by two way ANOVA, there was a significant
additive effect of VAC and ENR in decreasing Aβ 1-42 plaque load in the PFCTX
(F(1,34)=6.54 p=0.02), however by post hoc the E/V treatment group did not have
a lower plaque load than the C/V group, (p=1.000). In the presence of active
vaccine, the ENR group provides no additional benefit. But, where there was no
vaccine, the ENR treatment makes a difference such that Aβ1-42 plaque load is
lower. In other words, there is no additional effect of behavioral enrichment on the
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vaccine group, but in the absence of vaccine, ENR resulted in lower Aβ1-42 plaques
compared to the C/C group.
Total Aβ
Total Aβ (6E10) plaque load was measured in the PFCTS, OCTX, PCTX,
and ECTX in all animals. A significant decrease in total Aβ plaques was seen due
to VAC (both C/V and E/V groups) in all brain regions (PFCTX, F(1,34)= 52.91 p=
<0.001; OCTX, F(1,34)= 13.65 p= 0.001; PCTX, F(1,33)= 10.70 p= 0.003; ECTX,
(F(1, 34)= 6.60 p= 0.02) (Figure 6.11). When comparing the C/V group to C/C
animals, C/V dogs had lower plaque loads in the PFCTX, OCTX, and PCTX
(Bonferroni: p=<0.005, p=0.05, p=0.01 respectively) (Figure 6.11). ENR did not
have an effect on the reduction of total Aβ plaque load in any of the examined
regions (PFCTX, F(1,34)=2.95 p=0.10; OCTX, F(1,34)=0.34 p=0.57; PCTX,
F(1,33)=2.82 p=0.10; ECTX, F(1,34)=.23 p=0.64) (Figure 6.11). Though there was
no overall effect due to ENR, the E/V group did have lower total Aβ plaque loads
compared to the C/C group in the PFCTX, OCTX, and PCTX (Bonferroni:
p=<0.001; p=0.05; p=0.01 respectively) (Figure 6.11). No additive effects were
seen between VAC and ENR in decreasing total Aβ plaque loads from any of the
PFCTX (F(1,34)=1.78 p=0.19), OCTX (F(1,34)=0.13 p=0.73), PCTX (F(1,33)=3.26
p=0.08), or ECTX (F(1,34)=0.03 p=0.86) (Figure 6.11). The combination group,
E/V, did however have decreased total Aβ plaque loads compared to controls, C/C
(Figure 6.11).

Decreased total Aβ plaque loads was seen in the PFCTX

(p=<0.001), OCTX (p=0.03), and PCTX (p=0.01) (Bonferroni) (Figure 6.11).
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Pyroglutamate Modified Aβ
Previous immunotherapy studies did not look into the effects of the
treatment on post-translationally modified Aβ. Since post translationally modified
Aβ, more specifically AβpE3, is considered to be a more toxic and
chronobiologically older form of Aβ, we tested our vaccine on its ability to reduce
this form of Aβ. Here we measured AβpE3 plaques loads in the PFCTX, OCTX,
PCTX, and ECTX in all study animals.

We hypothesized that VAC would

significantly reduce AβpE3 plaque loads in all regions examined and more so in
the E/V treatment group dogs. We found that VAC had a significant effect in
decreasing AβpE3 plaques loads (Figure 6.12). AβpE3 plaque loads were
decreased in PFCTX (F(1, 30)= 10.00 p= 0.004) and PCTX (F(1, 29)= 6.50 p=
0.02), while no change was seen in the OCTX (F(1, 30)= 2.32 p= 0.14) or ECTX
(F(1, 30)= 3.13 p= 0.09) (Figure 6.12).

The C/V group trended towards a

significantly lower AβpE3 plaque load in the PCTX compared to that of the C/C
group (Bonferroni, p=0.06) (Figure 6.12). No reduction in plaque load was seen in
any regions examined due to ENR (PFCXT, F(1,30)=0.09 p=0.77; OCTX,
F(1,30)=0.84 p=0.37; PCTX, F(1,29)=1.30 p=0.26; ECTX, F(1,30)=1.59 p=0.22)
and or the combination therapy approach (PFCXT, F(1,30)=0.05 p=0.83; OCTX,
F(1,30)=1.32 p=0.26; PCTX, F(1,29)=2.33 p=0.14; ECTX, F(1,30)=2.65 p=0.11)
(Figure 6.12).
Comparison of Plaque Load Over Time Due to Treatments
As mentioned, PFCTX had lower Aβ1-42 plaque loads as an effect of ENR
that trended towards significance. In addition, though no ENR effect was
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statistically seen in lowering total Aβ plaque loads in the PFCTX and PCTX, the
E/C treatment group did have significantly lower loads than the C/C group. What
was unclear was if these lower plaque loads were due to a clearance of Aβ or
maintenance of pre-existing pathology by the ENR. In order to investigate this
further, we used PFCTX and PCTX tissue of archive cases that were age matched
to study cases at their baseline age and stained them for Aβ1-42 and total Aβ. The
results would provide measurements that would represent the Aβ 1-42 and total Aβ
plaque loads of the study cases at baseline before treatment began.
In the PFCTX, a significant group effect was seen when comparing Aβ1-42
(F(4, 44)= 9.447 p= <0.001) (Figure 6.13), total Aβ (F(4, 44)= 10.923 p= <0.001)
(Figure 6.14), and AβpE3 (F(4, 44)= 9.752 p= 0.009) (Figure 6.15) plaque loads
between the pre-treatment group to the study treatment groups. The pre-treatment
group had significantly lower Aβ1-42 (Bonferroni, p=0.050) (Figure 6.13) and total
Aβ (Bonferroni, p=0.014) (Figure 6.14) plaque loads than the C/C group indicating
that an increase in these plaque loads was seen with age. The plaque loads of
the pre-treatment group did not statistically differ from the E/C group, suggesting
that a maintenance effect due to the ENR was likely in keeping Aβ Aβ 1-42
(Bonferroni, p=1.000 ) (Figure 6.13) and total Aβ (Bonferroni, p=1.000 ) (Figure
6.14) plaque loads maintained compared to the C/C group (Figure 6.13). Similar
results were seen in the PCTX.

A significant group effect was seen when

comparing Aβ1-42 (F(4, 44)=4.780 p=0.003) (Figure 6.13), total Aβ (F(4, 44)= 3.297
p= 0.021) (Figure 6.14), and AβpE3 (F(4, 44)=3.321 p= 0.020) (Figure 6.15) plaque
loads between the pre-treatment group to the study treatment groups in the PCTX.
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Compared to the C/C group, the pre-treatment group had significantly lower Aβ142

(Bonferroni, p=035) (Figure 6.13) indicating that an increase in plaque load was

seen with age. As seen in the PFCTX, the pre-treatment group Aβ1-42 plaque load
did not differ significantly from the E/C group in the PCTX either, again suggesting
a maintenance effect due to ENR was likely keeping Aβ1-42 plaque loads lower than
the C/C group (Bonferroni, p=1.000 ) (Figure 6.13).
Soluble and Insoluble Brain Aβ
We hypothesized that the levels of soluble and insoluble Aβ in the brain would
be reduced due to VAC and that the E/V treatment group would show an even
greater reduction.

To test this hypothesis we measured PBS, SDS, and FA

extracted Aβ1-40 and Aβ1-42 from the PFCTX, OCTX, PCTX and HIPPO regions of
the brain by sandwich ELISA.
Aβ1-42
VAC significantly decreased Aβ1-42 in the PBS, SDS and FA extracts of the
PFCTX (PBS, F(1, 34)= 2.518 p= 0.016; SDS, F(1, 34)=31.244 p= <0.005; FA,
F(1, 34)=5.610 p= 0.024) and OCTX (PBS, F(1, 34)= 5.782 p= 0.023; SDS, F(1,
34)= 14.451 p= 0.001; FA, F(1, 34)= 3.914 p= 0.057), while the PCTX and ECTX
remained unchanged (Figure 6.13 A, C, E). No significant reduction was seen due
to ENR in PBS, SDS or FA extracted Aβ1-42 levels from any of the examined brain
regions. However, ENR increased SDS extracted Aβ1-42 in the HIPPO that trended
towards significance (F(1,34)=3.514 p=0.071) (Figure 6.16 B, D,F).

No

combination treatment effect was seen with VAC and ENR, except for a decrease
in SDS extractable Aβ1-42 in the PFCTX that trended towards significance
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(F(1,34)=3.461 p=0.073) and a significant increase in PBS extractable Aβ1-42 in the
HIPPO (F(1,34)=4.529 p=0.042). These results suggest that the VAC reduced
soluble and insoluble levels of Aβ1-42 in the PFCTX and OCTX. Additionally, the
combination treatment may have been effective in breaking down SDS extractable
Aβ1-42 into a more soluble state leading to increased PBS extractable Aβ1-42.
Aβ1-40
In addition to Aβ Aβ1-42, levels of soluble and insoluble forms of Aβ1-40 were
also measured. No significant decrease was seen due to VAC on Aβ 1-40 in any
fraction from the PCTX. There was a significant decrease in Aβ 1-40 extractable by
FA in the PFCTX (F(1, 34)=8.790 p= 0.006) and OCTX (F(1, 34)= 3.914 p= 0.057)
(Figure 6.17 E). However, no significant reduction due to VAC was seen in PBS or
SDS extractable Aβ1-40 in either of these regions (Figure 6.17 A and C). An
increase was seen in PBS extracted Aβ1-40 due to VAC in the HIPPO (F(1, 34)=
5.433 p= 0.027) (Figure 6.17 A). ENR had no effect on increasing or decreasing
PBS, SDS, or FA extractable Aβ1-40 in any of the brain regions of interest (Figure
6.17 B, D, F). Additive effects of VAC and ENR were only seen with increasing
SDS extractable Aβ1-40 in the PCTX (F(1,34)=6.150 p=0.019) and HIPPO
(F(1,34)=12.465 p=.001).

These results suggest that the VAC as well as

combination treatment may have been effective in breaking down FA extractable
Aβ1-42 into a more soluble state leading to increased levels of PBS (VAC) or SDS
(combo) extractable Aβ1-40.
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Aβ42/40 Ratio
The ratio of Aβ42/40 was calculated as an indicator of AD pathology and
onset of the disease (95, 217). A high Aβ42/40 ratio would indicate a greater
abundance of Aβ1-42 than Aβ1-40, while a low Aβ42/40 ratio would indicate greater
Aβ 1-40 levels in the brain. We hypothesized a lower Aβ 42/40 ratio in the VAC
animals since animals were vaccinated with fibrillar Aβ1-42 and a reduction of Aβ142

was expected. No significant changes were seen in the ratio of Aβ 42/40 in the

PBS, SDS, and FA extracted samples from the PCTX or OCTX (Figure 6.18 A, C,
E). There was a significant decrease due to VAC seen in PBS (F(1, 34)= 15.732
p= <0.005) and SDS (F(1, 34)=29.668 p= <0.005) extractable Aβ42/40 ratio in the
PFCTX (Figure 6.18 A and C). No increase or decrease due to ENR alone was
observed (Figure 6.18 B, D, F). However, a decrease in the ratio is found in
combination treatment of VAC and ENR in SDS extractable Aβ42/40 ratio
(F(1,34)=5.994 p=0.020). Interestingly, in the HIPPO, no increase or decrease
due to VAC was found, but a significant increase due to ENR was detected in PBS
extracted Aβ42/40 ratio (F(1,34)=5.101 p=0.031) (Figure 6.18 B). There is also an
additive effect due to VAC and ENR in increasing PBS extractable Aβ 42/40 ratio
(F(1,34)=5.066

p=0.032)

and

increasing

SDS

extractable

Aβ 42/40

ratio

(F(1,34)=7.668 p=.010). These results suggest that the ratio of Aβ 42/40 was overall
reduced in soluble extracts of the PFCXT due to VAC and the combination of VAC
ENR. In the HIPPO, an increase in PBS extracted Aβ 42/40 is seen which could
suggest the breakdown of less soluble forms seen in the SDS or FA extracts into
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more soluble Aβ seen in the PBS extract. Collectively these results support the
decrease in plaque loads seen in the PFCTX and HIPPO.
Microhemorrhages
Based upon previous studies in transgenic mice (320, 335, 482-484) and
human clinical trials (459) we hypothesized that C/V and E/V groups may have
more microhemorrhages than the C/C and E/C groups due to the vaccine. To
detect increased microhemorrhages, we stained sections from the PFCTX, OCTX,
and HIPPO brain regions using Prussian blue, which detects iron in the
extracellular matrix. Counts of the number of microhemorrhages were used to
detect treatment associated differences.
The total number of bleeds across all brain regions ranged between 0 and
23. The most bleeds was seen in the PFCTX having a range from 1 to 10 bleeds,
with the exception of one dog having 17 bleeds. This canine in particular was a
female, started the study at the age of 11.6 years, and was in the E/C treatment
group. The OCTX had similar bleed counts ranging from 0 to 7. Fewer bleeds
were seen in the HIPPO with a range of 0 to 3, with the exception of two dogs that
had 7 and 23 bleeds. The animal that experienced 7 bleeds was a male, started
the study at the age of 12.3 years, and was in the C/C group. The other dog that
experienced 23 bleeds in the HIPPO was a female, started the study at the age of
10.7 years, and was part of the E/V treatment group. Further, if a dog did show a
bleed in the HIPPO, it usually occurred in the CA3 region compared to area CA1
or dentate gyrus. Neither ENR (χ2(1)=0.025 p=0.876) (data not show) nor VAC
(χ2(1)=0.350 p=0.554) (Figure 6.19) significantly increased microhemorrhage
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frequency in the PFCTX. Additionally no individual group effect was seen on
increasing the number of microhemorrhage frequency (χ2(3)=0.984 p=0.805)
(Figure 6.20). There was also no change in the microhemorrhages in the HIPPO
due to ENR (χ2(1)=0.355 p=0.551) (data not shown), VAC (χ2(1)=0.078 p=0.780)
(Figure 6.19), or individual group (χ2(3)=0.853 p=0.837) (Figure 6.20). In the
OCTX, however, there was a statistically significant increase in microhemorrhages
due to VAC (χ2(1)=6.501 p=0.011) (Figure 6.19) and group effect (χ2(3)=8.372
p=0.039) (Figure 6.20). Though an increase in bleeds was statistically seen due
to VAC, neither the C/V nor E/V treatment groups show more microhemorrhages
than the C/C animals (Figure 6.20). However fewer microhemorrhages were seen
in the E/C animals in the occipital cortex compared to C/V animals (Figure 6.20).
It is possible that this decrease in bleeds of the E/C group (non VAC animals) could
have led to the statistically apparent higher frequency of bleeds due to VAC. No
increase in the number of microhemorrhages was observed due to a combination
treatment effect in the occipital cortex.
Comparison of Microhemorrhages Over Time Due to Treatments
With the finding that E/C group had fewer bleeds in the OCTX compared to
the other treatment groups and C/C group, we wanted to determine whether ENR
was reducing the number of bleeds seen or having a maintenance effect as
observed with plaque loads To do this we used the same 10 archive cases as used
for plaque load analysis that were age matched to study dogs at the start of the
study (10.5-13.6 years) (Pre-Treatment). We stained PFCTX and OCTX tissue
sections from these pre-treatment dogs with Prussian Blue.
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The total number of bleeds in the PFCTX from this pre-treatment group of
dogs ranged from 1 to 8, similar to numbers seen in the treatment groups and
control group. Statistically, there was no group difference in microhemorrhage
counts in the PFCTX between the pre-treatment group and the four study groups
(χ2(4)=1.103 p=0.894) (Figure 6.21).

In the OCTX, pre-treatment dogs only

showed 0 to 3 microhemorrhages compared to the 0 to 7 range seen in the study
dogs. There was the exception of one pre-treatment dog that had 5 bleeds. There
was a group difference in microhemorrhage frequency between the groups
including the Pre-Treatment group (χ2(4)=15.400 p=0.004) (Figure 6.21).
Additionally, the pre-treatment group showed approximately the same number of
microhemorrhages as the E/C treatment group (Figure 6.21). While the C/C, C/V,
and E/V treatment groups do not look to differ in number of bleeds, they do appear
significantly higher than the pre-treatment and E/C groups. This would suggest
that the E/C treatment is having a maintenance or protective effect against
microhemorrhages in the occipital cortex while all other treatment groups
experience more bleeds with age independently of the VAC.

Copyright © Paulina R. Davis 2014
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Figure 6.1. Landmark Discrimination Learning.
At Landmark 0, among, dogs that received ENR, dogs that received ENR
with VAC (E/V) had higher error scores than dogs receiving ENR only (E/C)
(t(16)=2.7 p=0.016). No group effect was seen for Landmarks 1,2, and 4. Overall,
higher error scores occurring as the landmark distance (and thus task difficulty)
increased (F(3, 42)=2.8 p=0.05).
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Figure 6.2. Variable distance landmark.
Dogs that received both VAC and ENR (E/V) did not differ in error scores for
the variable distance landmark task compared to those receiving only ENR (E/C).
Distance also had no effect on error scores during this task.
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Figure 6.3. Discrimination and reversal learning over time.
(A) In discrimination learning, error scores increased over time in all groups
(F(2,32)=3.4 p=0.05). No effect of the vaccine or of the behavioral enrichment
alone was seen, however there was a significant effect of the combination
treatment group (F(2, 32)=4.0 p=0.03). The combination treatment group had the
lowest error scores. (B) Reversal learning also indicated an increase in error
scores over time in all groups (F(2,30)=10.7 p<0.0005) 2 p=0.34). No treatment
effects were seen on error scores over time for VAC, ENR, or the combination
treatment. E/V treatment group had the highest error scores on reversal learning.
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Figure 6.4. Variable delay spatial memory task.
(A) No difference between treatment groups was seen in the accuracy of
performance across increasing delay intervals on the spatial memory task when
tested at baseline. (B) When re-tested 9.4 months into treatment, there was no
improvement observed due to VAC or ENR treatment alone or in combination. (C)
Testing after 18.1 months into treatment indicated an interaction between delay
interval and accuracy on the spatial memory task in the combination treatment
group (F(2,38)=3.62 p=0.04). However, this may be due to the poor accuracy of
the E/C and C/V groups during the 20s delay. (D,E,F) A decrease in accuracy
over time was seen for each delay interval (20 second delay, F(2,36)=16.12
p<.0005; 70 second delay, F(2,36)=5.51 p=0.008; 110 second delay,
F(2,36)=17.32 p<.0005).
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Figure 6.5. Anti-Aβ antibody titers over time as a function of treatment.
IgG response was measured in the serum of all animals over multiple
timepoints from baseline to euthanasia. VAC animals developed an anti- Aβ IgG
response over time (F(1,19)=12.5 p=0.002) and was maintained as a result of the
active vaccine (A). When observing all treatment groups, both VAC groups (C/V
and E/V) developed an antibody response and maintained it (B). However the E/V
response to the vaccine was delayed and did not reach the same maximum titers
as observed in dogs receiving the vaccine alone C/V.
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Figure 6.6. Change in average CSF Aβ1-40 over the course of treatment.
CSF Aβ1-40 was measured in all dogs across three time points through the
duration of treatment.

ENR led to a significant increase in CSF Aβ 1-40

(F(1,22)=5.76 p=0.03) (*) (A). VAC neither increased nor decreased the levels of
Aβ1-40 in CSF with the time points that were collected (B).
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Figure 6.7. Change in average CSF Aβ1-40 over course of study in all four treatment
groups.
No change in CSF Aβ1-40 was seen over time in any treatment group.
However, the combination treatment group E/V did have the greatest increase in
CSF Aβ1-40 by the end of the study.
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Figure 6.8. Change in average CSF Aβ1-42 over the course of treatment.
CSF Aβ1-42 was measured in all dogs across three time points through the
duration of treatment. No systematic effects were seen due to any treatment (A,
B).
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Figure 6.9. Change in average CSF Aβ1-42 over course of study in all four
treatment groups.
None of the treatments significantly changed CSF Aβ1-42 over time.
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Figure 6.10. Average Aβ1-42 plaque loads in PFCTX, PCTX, OCTX, and ECTX
regions of the brain.
Aβ1-42 plaque loads were reduced in most brain regions of VAC animals (C/V
and E/V) (PFCTX (F(1, 34)= 33.04 p= <0.001); OCTX (F(1, 34)= 14.92 p= 0.001);
PCTX (F(1, 33)= 14.06 p= 0.001) (*). No additive effect was seen due to the
combination of VAC and ENR (E/V). Though not as low as the C/V or E/V groups,
E/C animals did have lower loads of Aβ1-42 plaques than the C/C group in the
PFCTX (Bonferroni, p=0.02).
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Figure 6.11. Average total Aβ plaque loads in PFCTX, PCTX, OCTX, and ECTX
regions of the brain.
Total Aβ plaque load were reduced in the brains of VAC animals (C/V and
E/V) (PFCTX, F(1,34)= 52.91 p= <0.001; OCTX, F(1,34)= 13.65 p= 0.001; PCTX,
F(1,33)= 10.70 p= 0.003; ECTX, (F(1, 34)= 6.60 p= 0.02). No additive effect was
seen due to the combination of VAC and ENR (E/V). Lower levels of total Aβ
plaque loads were observed in the E/C group compared to the C/C group in the
PCTX (Bonferroni, p=0.06).
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Figure 6.12. Average pyro glutamate modified Aβ (AβpE3) plaque loads in PFCTX,
PCTX, OCTX, and ECTX regions of the brain.
Plaque levels of AβpE3 were overall lower than Aβ 1-42 and total Aβ plaque
levels in all regions of the brain. Though post-translationally modified, VAC was
able to reduce plaque loads containing this more toxic form of Aβ in the PFCTX
(F(1, 30)= 10.00 p= 0.004) and PCTX (F(1, 29)= 6.50 p= 0.02). E/C animals did
not differ in AβpE3 plaque loads from those of the C/C treatment group in any brain
region.
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Figure 6.13.

Changes in average Aβ1-42 plaque loads between Pre-

Treatment animals and treated study animals in PFCTX and PCTX regions of the
brain.
When comparing pretreatment animals to C/C, there is a significant increase
in Aβ1-42 plaque load with age (PFCTX, Bonferroni, p=0.050; PCTX Bonferroni,
p=035).

Pre-treatment animals did not differ from E/V animals suggesting a

possible maintenance of plaque loads over time due to ENR (PFCTX, Bonferroni
p=1.000; PCTX, Bonferroni, p=1.000).
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Figure 6.14. Changes in average total Aβ plaque loads between pre-treatment
animals and study animals in PFCTX and PCTX regions of the brain.
Pre-treatment animals had lower levels of total Aβ plaque loads compared to
control (C/C) animals in the PFCTX (Bonferroni, p=0.014), while there was no
difference compared to E/C animals (Bonferroni, p=1.000). This lack of change in
the E/C group suggests that ENR could be counteracting the natural age
dependent increase in total Aβ plaque loads as seen in C/C animals. No systematic
changes were seen in the PCTX for total Aβ plaque loads.
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Figure 6.15. Changes in average AβpE plaque loads between pre-treatment
animals and study animals in PFCTX and PCTX regions of the brain.
Significant group effects are seen in AβpE plaque loads between pretreatment animals and treated study animals in both the PFCTX (F(4, 44)= 9.752
p= 0.009) and PCTX (F(4, 44)=3.321 p= 0.020). There was very little AβpE in pretreatment dogs. While VAC reduced AβpE in treated animals compared to C/C or
E/C groups, levels do not return back to those seen before the start of the study
as represented by the pre-treatment group.

109

*

*

*

*

*
*

110

Figure 6.16. Soluble and insoluble brain Aβ1-42 as a function of treatment.
Higher levels of FA extractable brain Aβ 1-42 were seen compared to PBS
and SDS across all groups. VAC reduced all forms of extractable Aβ 1-42 in the
PFCTX (PBS, F(1, 34)= 2.518 p= 0.016; SDS, F(1, 34)=31.244 p= <0.005; FA,
F(1, 34)=5.610 p= 0.024)and OCTX (PBS, F(1, 34)= 5.782 p= 0.023; SDS, F(1,
34)= 14.451 p= 0.001; FA, F(1, 34)= 3.914 p= 0.057) (A, C, E). No change in
soluble or insoluble Aβ was seen due to ENR (B, D, F), except for an increase in
SDS extractable Aβ1-42 in the HIPPO (F(1,34)=3.514 p=0.071) that trended
towards significance (D).
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Figure 6.17. Soluble and insoluble brain Aβ1-40.
VAC increased PBS extracted Aβ1-40 in the HIPPO (F(1, 34)= 5.433 p= 0.027)
(A), while it reduced insoluble FA extractable Aβ1-40 in the PFCTX (F(1, 34)=8.790
p= 0.006) and OCTX (F(1, 34)= 3.914 p= 0.057) (E).
insoluble Aβ was seen due to ENR (B, D, F).
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Figure 6.18. Soluble and insoluble brain Aβ1-42/ Aβ1-40 Ratios
VAC decreases PBS (F(1, 34)= 15.732 p= <0.005) extractable Aβ 42/40 ratio
in the PFCTX(A), ENR increased PBS extracted Aβ 42/40 ratio (F(1,34)=5.101
p=0.031) in the HIPPO (B). SDS extractable Aβ 42/40 ratio in the PFCTX was
reduced by VAC (F(1, 34)=29.668 p= <0.005) (C). No increase or decrease due
to ENR was observed in SDS extractable Aβ 42/40 ratio (D). FA extractable Aβ
42/40 ratio was neither increased nor decreased by VAC or ENR (E, F).
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Figure 6.19.

Microhemorrhages frequency in the PFCTX, OCTX, and Hippo

regions of the brain in VAC treated animals compared to non VAC treated animals.
VAC does not cause an increase in microhemorrhages in the PFCTX or
Hippo regions of the brain. However, VAC appears to increase the number of
microhemorrhages in the OCTX but there was significant individual variability
(χ2(1)=6.501 p=0.011).
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Figure 6.20.

Microhemorrhage occurrence in the PFCTX, OCTX, and Hippo

regions of the brain as a function of treatment group.
No increases in microhemorrhage frequency in the PFCTX or Hippo were
seen as a consequence of treatment. While VAC increases bleed events in the
OCTX (χ2(1)=6.501 p=0.011), the number of bleeds observed in VAC animals (C/V
and E/V groups) does not differ significantly from the control animals (C/C)
(Bonferroni- C/V, p=0.852; E/V, p=1.000). However, the E/C treatment group
showed fewer microhemorrhages in the OCTX than the C/C group (Bonferroni,
p=0.071) suggesting that ENR may be protective in that region of the brain.
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Figure 6.21. Microhemorrhage occurrence in the PFCTX and OCTX regions of the
brain in pre-treatment and study animals.
In the PFCTX there were no differences in microhemorrhages between any
of the treatment groups. However, in the OCTX, pre-treatment and E/C animals
trends towards having fewer microbleeds than C/C and VAC dogs. Since E/C
animals appear to show the same frequency of microbleeds as the pre-treatment
animals, we suggest that the ENR is maintaining brain health and preventing
microhemorrhages that may naturally occur with age.
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CHAPTER SEVEN: Discussion
Previous human clinical trials using active vaccination with fibrillar Aβ1-42,
though discontinued due to cases of meningoencephalitis, showed evidence of
reduced Aβ pathology within the brain (135, 181).

Consequently, passive

immunization approaches that eliminate the possibility of the previous adverse
events have been and are currently being investigated in patients with mild to
moderate AD; these immunotherapies reduce Aβ pathology and show modest
reductions in rates of cognitive decline (101, 103, 366, 367). While these passive
immunotherapies do not lead to meningoencephalitis, they have caused
microhemorrhaging in several patients as seen by magnetic resonance imaging
(368, 420). Our lab has investigated active immunization in aged canines using
an adjuvant that is safe for use in mice and humans having few adverse effects
(24, 83, 177, 246). In a previous study in aged canines, active vaccination with
fibrillar Aβ1-42 using Alum as an adjuvant reduced Aβ pathology in the brain and
helped maintain executive function without causing adverse effects such as
meningoencephalitis as seen with past active vaccinations (177). However,
improved cognition in response to the vaccine was not observed in the canine
study as reported in transgenic mouse studies (198, 286). Thus, it is possible that
the vaccine alone and reduction of Aβ was insufficient to improve cognition in aged
dogs with neuropathology. We hypothesized that adding a second intervention that
would lead to neuronal repair may be beneficial when combined with the vaccine.
We focused on behavioral enrichment as a second “arm” to this study.
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Behavioral enrichment, consisting of exercise, cognitive enrichment, social
engagement, and environmental enrichment, is being evaluated in clinical trials for
AD in humans and animal models. Exercise and environmental enrichment
improve learning in rodents but shows variability between studies in AD mouse
models (17, 80, 239).

In humans, behaviorally enriched lifestyles, involving

exercise, cognitive enrichment, and social engagement, helps reduce brain
atrophy with age and reduces risk of dementia (165, 274). Furthermore, in canines,
ENR improves cognitive function without affecting Aβ levels in the brain (71, 485).
While immunotherapies reduce Aβ pathology in humans and animals as well as
aid in cognitive maintenance, ENR improves cognition and reduces risk of
dementia but has variable outcomes on levels of brain Aβ. This study sought to
combine active VAC with ENR predicting they would build upon one another and
lead to greater cognitive improvement as well as decreased Aβ pathology
compared to each individual treatment alone.
One aspect of the combination therapy we wanted to test was its effects on
cognition. Based on our previous studies, ENR improves overall cognition in aged
canines (71, 485).

However, in a previous canine active vaccine study, no

improvements in cognition were observed (177). We had hypothesized that our
study animals receiving ENR only or VAC only would show similar results to past
studies but animals receiving both ENR and VAC would exhibit greater cognitive
improvements.

Our results however, indicated no systematic effects by any

treatment on improving cognition. The lack of cognitive improvement in the E/C
group came as a surprise. It was noted however, that all tested animals actually
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performed better with lower error scores at baseline than dogs in past studies did
during their baseline testing. Also, housing protocols and the diet now provided
for research canines has improved substantially since our last ENR study. It is
possible that the housing conditions have improved enough that an ENR threshold
has been met between all treatment groups just through these conditions where
no additional cognitive benefits can occur even with added social engagement or
cognitive enrichment.

Results from the current study strongly suggest that

reversing age-associated and Aβ-dependent cognitive decline is challenging and
prevention may be more beneficial. Results from our neurobiological studies
support this conclusion as will be discussed next.
After 19 months of treatment with the active vaccine of fibrillar Aβ1-42, VAC
animals had increased antibody titers against fibrillar Aβ 1-42. In C/V animals, this
response was first seen at 4 weeks after treatment, while the E/V treated dogs
experienced a delayed response at 2 months. While both groups receiving VAC
maintained antibody levels through the rest of the study, the maximum response
of the E/V treatment group never reached that of the C/V treatment group. It is
possible that ENR in the combination treatment suppressed the immune response
initiated by the vaccine causing a lower maximum antibody response but was still
sufficient to reduce brain Aβ to the same extent as the C/V group. Overall, the
elevated levels of anti- Aβ1-42 antibodies indicate that the active vaccination was
successful in initiating the production of antibodies against fibrillar Aβ 1-42. This
result mirrors that of the human trials using active vaccination, where patients
showed an antibody response between one and two months after treatment (181).
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CSF Aβ levels correlate with disease in patients with AD who show lower
CSF Aβ levels than non-demented individuals (for review, see (14)). To monitor
Aβ changes throughout treatment, CSF samples were collected before treatment,
12 months into treatment, and at euthanasia. We hypothesized that VAC animals
would have higher Aβ levels than non-VAC animals. These expected results would
suggest the vaccine was succeeding in removing the Aβ from the brain and moving
it into the periphery. However, VAC did not lower or raise CSF Aβ1-42 or Aβ1-40
compared to dogs that did not receive VAC. Several contributing factors may exist
for these unexpected results. Samples were only able to be drawn at two time
points before euthanasia. It is possible that levels of CSF Aβ may have become
elevated at some time between the baseline and 12 months collection time points
as Aβ was cleared from the brain. This elevation would then be followed by a
reduction once a majority of Aβ was removed from the brain and periphery.
Essentially, once Aβ was cleared from the brain and into the periphery, Aβ would
also be removed from the CSF. This possible mechanism could have been
captured had additional time point collections of CSF been made. Unfortunately,
in order to collect CSF, the animals must be sedated, which can be physiologically
stressful for aged animals. For this reason, CSF draws were limited to three
spaced out collection time points.
While VAC did not reduce CSF Aβ1-42 or Aβ1-40, ENR did increase CSF Aβ140.

As discussed earlier in Chapter 2, Aβ1-40 is the prominent isoform of Aβ peptide

involved in amyloidosis in the vasculature of the brain (324, 389, 498). One
possible explanation for the increased CSF Aβ 1-40 is that the exercise component
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of the ENR improved blood perfusion and cerebrovascular health and aided in the
clearance of Aβ deposited in the vasculature to the periphery. Additionally, this
increase in CSF Aβ1-40 was selective and not seen with Aβ1-42. Since Aβ1-42 tends
to form plaques in the parenchyma of the brain rather than within blood vessels,
this lack of effect by ENR on CSF Aβ1-42 further supports the idea of ENR acting
specifically on the cerebrovasculature. (324, 389, 477).
Several active and passive immunotherapies studied as a therapeutic for AD
have shown positive results in reducing Aβ plaque pathology in both animal models
and patients with AD (94, 177, 341, 367, 368, 381, 403, 438). In the present study,
use of active immunization with fibrillar Aβ1-42 in combination with ENR to treat
aging canines also reduces Aβ pathology in several regions of the brain. VAC
treated dogs, including both the C/V and E/V treatment groups, had decreased Aβ
plaque loads compared to non-immunized animals in the PFCTX (Aβ1-42 and total
Aβ), OCTX (Aβ1-42 and total Aβ), PCTX (Aβ1-42 and total Aβ), and ECTX (total Aβ)
regions of the brain. In addition, AβpE3, post-translationally modified Aβ, was
reduced in the PFCTX and PCTX regions of the brain in VAC animals. Previous
vaccine studies using the canine model have not explored the vaccine’s potential
in reducing post-translationally modified Aβ. Post-translationally modified Aβ,
including AβpE3, has shown to be more toxic and involved in the initial stages of
the disease thereby making it a crucial therapeutic target for clearance in a clinical
setting (8, 162, 362, 383, 385, 487).
The previous ENR study in aged canines did not exhibit any kind of reduction
in Aβ pathology in response to treatment (322). Interestingly, in the current study
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ENR showed a trend towards reducing Aβ1-42 in the PFCTX. ENR led to reduced
total Aβ plaque loads in the PFCTX and PCTX. However, ENR did not show any
treatment effects in reducing AβpE3.

With this finding we became curious if the

lower Aβ pathology was due to a clearance effect or maintenance effect due to the
ENR. Since this reduction due to ENR seen in our study was not as great as that
seen by VAC, we hypothesized that the ENR had a maintenance effect on Aβ
plaque loads rather than a clearance effect.
To test if ENR was having a maintenance or clearance effect on plaque loads,
we used PFCTX and PCTX brain tissue (regions that appeared to have the
greatest treatment effect by ENR) from 10 canine cases from our archive tissue
inventory. Dogs were selected at matched ages to the baseline ages of the
treatment study animals. These pre-treatment dogs represented the average
plaque loads of the treatment study dogs prior to the start of treatment, providing
a means of comparing change in plaque loads with age (with C/C group dogs) and
with treatment (with E/C, C/V, and E/V group dogs).
Results showed that pre-treatment dogs exhibited significantly lower plaque
loads than C/C dogs for all types of Aβ examined illustrating the increase of plaque
loads in the canine with age over time. Aβ1-42 plaque loads of the PFCTX in pretreatment dogs most resembled that of the E/C treatment group suggesting that
the effects seen by ENR were likely maintenance of plaque loads in treated dogs
rather than a clearance of Aβ plaques. This maintenance could have either been
a decreased rate of Aβ accumulation or slowing of Aβ accumulation. Aβ1-42 plaque
loads in the PCTX of the pre-treatment animals fell between the E/C treatment
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group and VAC animals. However, the E/C group loads were still lower than that
of the C/C group. It is likely that the ENR was able to slow the rate of Aβ1-42 plaque
formation in the PCTX while VAC cleared plaque loads.

A similar effect is

suggested with total Aβ plaque loads in the PFCTX and PCTX. Unlike the Aβ1-42
and total Aβ plaque loads, AβpE3 average plaque load for the pre-treatment group
was significantly lower than all treatment groups on the present study. ENR
appears to have no effect on AβpE3 plaque loads, while the VAC reduced/cleared
this post-translationally modified form of Aβ (VAC animals). The lack of change in
AβpE3 plaque loads suggests that ENR was not affecting preexisting Aβ, but
rather the further accumulation of Aβ plaques. These results support ENR having
a maintenance effect rather than enhancing clearance.
Aβ found in the periphery is of soluble form, however, both soluble and
insoluble Aβ are found in the brain (262, 294, 390, 473). Plaque loads do not
provide us with information regarding the changes in soluble as compared to
insoluble Aβ. Though insoluble Aβ primarily makes up plaque pathology, this form
of Aβ may not all be aggregated into plaque and can also be found in blood
vessels. Additionally, plaque loads do not provide insight on soluble Aβ levels
since this form of Aβ is not associated with plaques (262, 294, 390, 473). To further
investigate the combination treatment effects of the present study serial extracted
soluble and insoluble Aβ was measured in all treatment groups. We found that
VAC reduced both soluble (PBS and SDS extracts) and insoluble (FA extract) Aβ142

from the PFCTX and OCTX compared to non VAC dogs. Our findings confirmed

the earlier mentioned clearance of Aβ1-42 plaques seen by VAC in these brain
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regions.

While we saw a reduction in Aβ1-42 plaques that trended towards

significance in the PFCTX due to ENR, we did not see any effect by ENR on
reducing FA extracted insoluble Aβ1-42 in this brain region or any other examined
region supporting the hypothesis of maintenance and not clearance of Aβ
pathology.
We did not see a reduction in FA extracted Aβ 1-40 due to VAC, however, an
increase of PBS extracted Aβ1-40 was seen. This increase in soluble Aβ1-40 could
be the result of breaking down plaques by the VAC into more soluble forms of Aβ.
While we saw an increase in soluble Aβ1-40 in the CSF of ENR treated dogs, we
did not see the expected decrease in insoluble or soluble Aβ1-40 in any brain region
of these dogs. As discussed earlier, the increase in CSF Aβ 1-40 may have been
due to the clearance of deposited Aβ in the cerebrovasculature by ENR benefits
on vascular health. If this is the case, then any insoluble Aβ 1-40 deposited in blood
vessels would be broken down into a soluble state and be more readily cleared
from the brain and into the periphery than that of which is deposited in the
parenchyma of the brain. While this clearance of vascular deposited Aβ could lead
to a noticeable increase in peripheral Aβ1-40, as seen in the CSF of ENR animals,
it may not be enough to indicate an apparent decrease in insoluble brain Aβ 1-40.
This would explain the lack of difference in the serial extracted Aβ in the brain due
to ENR.
Using the measurements of Aβ1-42 and Aβ1-40 we calculated the Aβ 42/40
ratio. Generally Aβ 42/40 ratio is an indicator of AD pathology and onset of the
disease (95, 217). In dogs, it is expected that this ratio would be higher with age
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as pathology and cognitive decline progress. Since the VAC dogs in our study
received vaccinations of fibrillar Aβ1-42 and had shown reduced levels of Aβ1-42, we
hypothesized that the Aβ 42/40 ratio would be lower in VAC treated animals than
non-treated animals. Aβ 42/40 ratios for PBS and SDS extractable Aβ were lower
in the PFCTX of VAC treated animals. With these results we could conclude that
the VAC was most productive in reducing Aβ pathology specifically in the PFCTX,
which is portrayed in the reduction of plaque forms and serial extracted Aβ in the
PFCTX. While no change was seen in Aβ 42/40 ratios for the PCTX, OCTX, or
HIPPO of the VAC animals, these regions did still show reduced plaque loads or
soluble and insoluble Aβ.
While both VAC and ENR had their respective treatment effects on CSF Aβ,
Aβ plaque load, serially extracted Aβ, and overall reduction of Aβ pathology, no
significant additive effects were seen in the combination treatment group in further
reducing Aβ pathology. Statistically by two way ANOVA, there was a significant
additive effect of VAC and ENR in decreasing Aβ 1-42 plaque load in the PFCTX,
decreasing SDS extractable Aβ1-42 and Aβ 42/40 ratio in the PFCTX, increasing
PBS extractable Aβ1-42 and Aβ 42/40 ratio in the HIPPO, and increasing SDS
extractable Aβ1-40 in the PCTX and HIPPO.

However, by post hoc the E/V

treatment group did not have greater effects than the C/V group. In the presence
of active vaccine, the ENR provides no additional benefit.
The results of our study further support the ability of active vaccination with
fibrillar Aβ1-42 combined with Alum to reduce Aβ pathology in aged canines.
Additionally the vaccine in our study does not promote adverse effects similar to
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the meningoencephalitis that was seen in the human clinical trials using an active
vaccine with QS-2 in polysorbate 80 as an adjuvant. However, there was still the
concern of intracerebral microhemorrhages due to the use of immunotherapies for
treatment of AD. Such an increase in microhemorrhages could increase risk of
intracerebral microhemorrhage and further cognitive impairment (39, 469). We
examined the frequency of microhemorrhages in the PFCTX, OCTX, and HIPPO
regions of the brains in all study dogs along with the added pre-treatment archive
cases in order to determine if an increase in microhemorrhages would occur with
the use of the active vaccination with fibrillar Aβ 1-42 in Alum. Microhemorrhages
appeared to be more frequent in the PFCTX and OCTX than the HIPPO of study
dogs. The PFCTX and OCTX are regions of the brain where Aβ deposition is
thought to occur first with age (18, 50-52, 445). Since microhemorrhages do occur
with age and with greater Aβ deposition in the vasculature of the brain, it was not
surprising to see these regions having the greater number of microhemorrhages
compared to the HIPPO. Neither VAC nor ENR led to an increase in
microhemorrhages in the PFCTX or HIPPO. There was a statistically significant
increase in microhemorrhages in the OCTX due to VAC. However, the C/V and
E/V treatment groups did not differ in microhemorrhage occurrence compared to
the C/C group.

What was apparent was the lower number of OCTX

microhemorrhages in the E/C treatment group compared to the other groups. It’s
possible that this lower frequency of microhemorrhages in the E/C drove the
statistical increase in microhemorrhages due to VAC since the E/C group is
considered part of the non-VAC animals. Using the same baseline age match
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archive cases that were in the plaque load analysis, we were able to determine if
the lower microhemorrhage frequency in the E/C group was due to a maintenance
effect of treatment. Pre-treatment dogs showed a similar frequency of
microhemorrhages in the OCTX as the E/C treatment group. This observation
suggests that ENR shows maintenance or protective effects against additional
microhemorrhages while all other treatment groups experienced more bleeds with
age independently of VAC.
Although no significant or consistent cognitive benefits were detected in any
treatment group, the active vaccine successfully produced antibody responses
against fibrillar Aβ1-42. Vaccinated animals also showed a reduction in overall Aβ
pathology in multiple areas of the brain, while not showing an increase in CSF Aβ.
Previous immunotherapy studies in animals or humans had investigated the
potential ability to reduce modified Aβ pathology such as plaques consisting of
AβpE3. Here we show that active vaccination with fibrillar Aβ1-42 is successful in
reducing a toxic and highly aggregated form of modified Aβ in the canine model.
In addition to the vaccine treatment, those receiving ENR showed a lack of ageassociated increase in Aβ pathology that has not been reported in past ENR
studies in dogs. ENR led to an increase in CSF Aβ 1-40 possibly suggesting ENR
aiding in the clearance of deposited Aβ in the vasculature. ENR also slowed the
age associated increase of Aβ1-42 plaque load in the PFCTX with treatment. In the
HIPPO, ENR decreased SDS extractable Aβ1-42 in the HIPPO. As for the concern
for potential adverse effects of immunotherapy for AD, no serious negative effects
were seen and frequency of microhemorrhage occurrence was not increased with

129

the use of active vaccination with fibrillar Aβ1-42 in Alum. Additionally, we found that
ENR may actually reduce the risk of microhemorrhages in the OCTX region. While
benefits of both VAC and ENR were experienced in reducing Aβ pathology, the
combination of both treatments did not cause any additional benefit compared to
using only single treatment of either VAC or ENR. Additionally, no synergistic
improvement was detected in cognitive function in the combination treatment
group compared to individual treatment groups.
Many therapeutic approaches have at best, modestly improved cognitive
function in larger animal models of AD. This lack of cognitive improvement is
consistent with clinical trials with AD patients. It is possible that once Aβ has begun
its damage to neurons it is challenging to reverse it and restore cognition that has
already been compromised. Either alternative therapeutic approaches need to be
explored, or treatment may need to be initiated earlier as a preventative approach
before the Aβ pathology begins or worsens.
The combination treatment we use in this study may better serve as a
preventative therapy for AD. Our results from the ENR treatment strongly support
a maintenance effect that likely works on a mechanism completely separate to that
by which the VAC component of the combination therapy did. While the ENR
appears to be acting on the mechanism of Aβ accumulation, the VAC works by
clearing pre-existing Aβ pathology. Together, the combination treatment could be
a viable therapeutic approach for the prevention of AD. With the age of onset for
AD pathology varying between individuals, determining a timeline for
administration of a preventative treatment becomes difficult. Using a combination
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therapy approach such as ENR with VAC could target both the prevention of Aβ
accumulation as well as the clearance of any likely little pre-existing Aβ pathology.
This type of treatment approach could allow for some flexibility when determining
a timeline for administering the treatment in a given individual. Ultimately, the
treatment could act early enough to prevent any possible irreversible damage
being done to the neurons by the Aβ pathology and avoid resulting cognitive
deficits.

Copyright © Paulina R. Davis 2014

131

CHAPTER EIGHT: Future Directions
While the approach of using VAC in combination with ENR in this study did
not lead to additive effects in reducing Aβ pathology or improving cognition in aged
canines, we did see interesting and novel cerebrovascular benefits due to ENR
that had otherwise not been seen in the previous canine study. It would be of great
interest to measure the amount of blood vessel Aβ pathology in the study animals
and determine if there is a correlation between these levels and increased CSF
Aβ1-40. We would hypothesize that there would be a correlation between lower
levels of blood vessel pathology and increased levels of CSF Aβ 1-40 and that this
correlation would be seen in animals receiving ENR. Additionally, the changes in
Aβ plaque pathology seen due to ENR indicate that a maintenance effect is likely
occurring in ENR treated animals. To further investigate this maintenance idea, αand β-secretase activity could be measured. In a previous canine study exploring
the effects of an antioxidant diet and ENR on Aβ load, α- secretase activity was
increased in animals receiving ENR (322).

For the current study we would

hypothesize that ENR is promoting α-secretase activity resulting in ENR animals
having lower β-secretase activity and increased non-amyloidogenic processing
compared to non-ENR animals.
The focus of this study was to examine effects on cognition and Aβ pathology
due to the combination treatment.

Other neurological changes that have

previously been reported in past ENR studies have not yet been explored in these
animals. For instance, although neurogenesis was not increased with ENR in a
previous aged canine study, neuron number in the hippocampus and the growth
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factor BDNF are maintained and improved, respectively, in ENR treated dogs
(116, 278, 279, 407). Future directions of this project would be to explore these
changes in the present study animals and comparing those in the E/V treatment
group to all other groups. One could hypothesize that the both the E/C and E/V
treatment groups would show higher levels of BDNF and potentially enhanced
neuron survival and neurogenesis, with the E/V group experiencing greater
improvement.
It was noted that the VAC was successful in reducing modified Aβ, AβpE3,
pathology that has been previously shown to be more toxic. Additionally, AβpE3
correlates with the hyperphosphorylation of tau. Though canines do not produce
NFTs with age, they do show hyperphosphorylation of tau at sites that coincide
with those affected in humans with AD. It would be of interest to measure levels
of soluble and insoluble tau in our treated canines and see if a correlation exists
between these measures and the effects of VAC on AβpE3 plaque pathology. One
could hypothesize that levels of insoluble tau in C/C and E/C treatment groups
would be higher than those of the C/V and E/V treatment groups. The effects of
VAC in reducing AβpE3 pathology could lead to the de-hyperphosphorylation of
tau or the prevention of additional hyperphosphorylated insoluble tau.
As mentioned earlier, the combination approach tested in the current study
may have exhibited greater additive effects, particularly on cognition, had the
treatment been started at an earlier age in the canines. As a future project, this
combination treatment could be tested in canines around 7 to 8 years old, just as
Aβ begins to accumulate. At this age, Aβ pathology should be minimal and
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cognitive changes would be predicted to be mild. ENR started at this age would
promote healthier brain aging as earlier studies have shown ENR improve
neurogenesis and reduced neuronal loss (116, 408). From our findings in this
study, ENR should also reduce the risk of microhemorrhage occurrence which can
contribute to cognitive decline. Additionally ENR prevented or slowed the rate of
Aβ plaque accumulation and would be hypothesized to aid in preventing Aβ in
younger canines. With ENR and VAC acting on separate pathways, one could
hypothesized the resulting immune response would further assist in preventing
additional Aβ pathology and clearing out any pre-existing early Aβ plaque
formation before any neuronal damage could occur.

Copyright © Paulina R. Davis 2014
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